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ABSTRACT 
The aim of this thesis study was to gain more information on the physiological and 
toxicological functions of the aryl hydrocarbon receptor (AHR). The effects of two 
novel selective AHR modulators (SAHRMs) were investigated in vitro and in vivo. In 
addition, the involvement of the AHR in the avoidance of novel food was examined. 
The AHR is an evolutionarily ancient, apparently over 600-million-year-old 
protein. It is a ligand-activated transcription factor that modulates the expression of 
various genes within cells. One of the most studied groups of compounds that activate 
the AHR are dioxins. They are environmental contaminants primarily formed as by-
products of various industrial processes, and many of them are toxic. Dioxins are 
chemically very persistent and lipid soluble, and thus accumulate in the food chain. 
Therefore, humans are also exposed to small amounts from food. In Finland, the most 
common source of dioxins is fatty wild fish from the Baltic Sea. 
The AHR has been recognised as the mediator of dioxin-induced toxicity for 
decades. More recently, it has also been shown to be involved in several physiological 
functions of the body, including the regulation of reproduction, foetal development, 
the immune system and autoimmunity. However, our understanding of the 
mechanisms of both the toxicological and physiological functions of the AHR remains 
incomplete. As a consequence, for instance, human health risk assessment of dioxins 
is challenging. Furthermore, better understanding of the physiological effects of the 
AHR could help elucidate the aetiology and pathogenesis of certain diseases, and 
therefore also benefit the discovery of novel pharmacological therapies. 
As lead compounds for drug discovery, SAHRMs are particularly interesting. They 
only elicit subsets of AHR-mediated effects, often without the major toxic outcomes 
of dioxins. Moreover, they could be valuable tools in elucidating the so far 
incompetently understood, multifaceted physiological roles of AHR, and the 
underlying molecular mechanisms. 
This thesis research had two main objectives. The first was related to studying the 
in vitro and in vivo toxicity of two novel SAHRMs, which are intended as drug 
compounds for the treatment of autoimmune diseases. The aim was to determine 
whether they appear suitable for pharmacological use from the pre-clinical safety 
perspective. Furthermore, finding out the extent to which their effects resemble or 
differ from those of the most toxic dioxin, TCDD, was of interest. The second objective 
was to accumulate more knowledge on a peculiar novel food avoidance behaviour, 
previously characterised in rats and mice after exposure to TCDD. This behaviour 
resembles a recognised behaviour model, conditioned taste aversion (CTA), which is 
also exhibited in humans, for instance in conjunction with nausea related to cancer 
treatment. The aim here was to verify whether the aforementioned rodent response 
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is a physiological effect of the AHR or, more specifically, a consequence of TCDD 
exposure. 
Based on the results, the novel SAHRMs are very effective AHR activators, both 
in vitro and in vivo, and are in fact comparable to TCDD. However, their toxicity 
profiles are distinct from that of TCDD, and they appear considerably less toxic in 
rats. Therefore, the novel SAHRMs appear promising as possible drug compounds, 
and also highly interesting as tools for AHR research. Despite the differences in 
toxicity, one of the novel SAHRMs, as well as all of the three other AHR activators 
tested in this study, induced a strong avoidance response resembling that previously 
observed to TCDD, but shorter lasting. In addition, the reaction was not inducible in 
AHR knock-out rats. Thus, this study confirmed that the novel food avoidance 
behaviour is mediated by the AHR. The effect appears protective against potentially 
harmful ingested foods, and is therefore another physiological function of the AHR. 
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TIIVISTELMÄ 
Tämän väitöskirjatutkimuksen tarkoituksena oli saada lisätietoa 
aryylihiilivetyreseptorin (AHR) fysiologisista vaikutuksista elimistössä sekä sen 
kautta välittyvän toksisuuden mekanismeista. Tutkimme kahden uuden, valikoivasti 
AHR:n toimintaa säätelevän lääkeainekandidaatin vaikutuksia. Lisäksi 
tarkastelimme AHR:n osallisuutta aiemmin kuvatussa, uusien ruoka-aineiden 
karttamisreaktiossa. 
AHR on evolutiivisesti muinainen, ilmeisesti yli 600 miljoonaa vuotta vanha 
proteiini, joka säätelee soluissa lukuisten geenien ilmentymistä. Yksi eniten 
tutkituista AHR:n toimintaa aktivoivista aineryhmistä on dioksiinit. Ne ovat 
ympäristölle ja terveydelle haitallisia yhdisteitä, joita syntyy pääasiassa lämpö- ja 
teollisuusprosessien sivutuotteina. Koska ne ovat kemiallisesti erittäin pysyviä ja 
hyvin rasvaliukoisia, ne kertyvät ravintoketjuissa, ja siten myös ihmiset altistuvat 
niille ravinnon välityksellä. Suomessa tavallisin dioksiinien lähde on Itämeren 
rasvainen villikala. 
AHR on tunnettu dioksiinien aiheuttamien myrkyllisten vaikutusten välittäjänä 
jo pitkään. Sittemmin sillä on osoitettu olevan myös lukuisia elimistön normaalin 
toiminnan kannalta tärkeitä fysiologisia tehtäviä, muun muassa lisääntymisen 
säätelyssä, yksilönkehityksessä, autoimmuniteetissa ja immuunipuolustuksessa. 
Fysiologisten tehtävien, samoin kuin AHR:n välittämien toksisten vaikutusten 
mekanismien tuntemus on kuitenkin toistaiseksi puutteellista, mikä muun muassa 
vaikeuttaa dioksiinien ihmisille aiheuttamien terveysriskien arviointia. AHR:n 
fysiologisten vaikutusten parempi tuntemus voisi lisäksi auttaa tiettyjen sairauksien 
syntymekanismien selvittämisessä ja siten edistää uusien lääkehoitojen kehitystä.  
Selektiivisesti AHR:n toimintaa säätelevät aineet ovat lääkekehityksen kannalta 
erityisen kiinnostavia, sillä monet niistä aktivoivat AHR:ää aiheuttamatta 
dioksiineille tyypillisiä haittavaikutuksia. Lisäksi ne voivat olla hyödyllisiä työkaluja 
AHR:n fysiologisten vaikutusten tutkimisessa. 
Tällä väitöskirjatutkimuksella oli kaksi päätavoitetta. Ensimmäinen liittyi kahden 
uuden, AHR:ää valikoivasti aktivoivan lääkeainekandidaatin toksikologisten 
vaikutusten tutkimiseen. Tarkoituksena oli selvittää, vaikuttavatko ne 
toksisuusprofiilinsa puolesta sopivilta lääkeaineiksi, jolloin niitä voitaisiin edelleen 
kehittää esimerkiksi autoimmuunisairauksien hoitoon. Lisäksi olimme 
kiinnostuneita selvittämään, missä määrin näiden aineiden aiheuttamat vaikutukset 
muistuttavat tai poikkeavat myrkyllisimmän dioksiinin, TCDD:n, aiheuttamista 
vaikutuksista. Toisena tavoitteena oli syventää tietoa aiemmin rotilla ja hiirillä 
TCDD-annostelun jälkeen havaitusta uusien ruoka-aineiden karttamisreaktiosta, 
joka muistuttaa ennestään tunnettua käyttäytymismallia, ehdollistettua 
makuaversiota (CTA). Samankaltainen makuaversio tunnetaan myös ihmisillä muun 
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muassa syövän hoitoon liittyvän pahoinvoinnin yhteydessä. Halusimme varmistaa, 
johtuuko edellä mainittu jyrsijöiden reaktio yleisesti AHR-aktivaatiosta vai onko se 
ainoastaan TCDD:lle ominainen vaikutus. 
Tulosten perusteella edellä mainitut uudet, selektiiviset AHR-modulaattorit ovat 
tehokkaita, TCDD:n veroisia AHR-aktivaattoreita. Toksisuusprofiililtaan ne ovat 
kuitenkin olennaisesti TCDD:tä haitattomampia ja vaikuttavat siten kiinnostavilta 
lääkeainekandidaateilta. Havaituista eroista huolimatta sekä toinen niistä että muut 
tässä työssä testatut AHR-aktivaattorit aiheuttivat TCDD:n tavoin voimakkaan, 
joskin lyhytkestoisemman, uusien ruoka-aineiden karttamisreaktion. Lisäksi reaktio 
puuttui AHR-poistogeenisiltä rotilta. Tulos vahvistaa, että tämä mielenkiintoinen 
vaikutus on AHR-välitteinen. Tämä käyttäytymismuutos suojaa ilmeisesti eliöitä 
haitalliselta vaikuttavan ravinnon nauttimiselta ja on siten uusi AHR:n fysiologinen 
vaikutus. 
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1  INTRODUCTION 
Research on the aryl hydrocarbon receptor (AHR) started in the 1970s, when this 
protein, a ligand-activated transcription factor, was first discovered (Poland et al. 
1976). Initially, it was found to mediate the induction of xenobiotic metabolising 
enzymes in response to a large group of environmental contaminants, encompassing 
halogenated and polycyclic aromatic hydrocarbons, which are mostly by-products of 
industrial thermal processes and incomplete combustion (Kulkarni et al. 2008). 
Soon, the AHR was also established as the mediator of toxicity triggered by these 
compounds (Poland and Knutson 1982), of which dioxins (polychlorinated dibenzo-
p-dioxins, dibenzofurans and co-planar PCBs) are particularly important. This 
initiated a rapidly emerging field of research, where the various toxic effects induced 
by dioxins were characterised in several laboratory animal species. The model 
compound largely used in these studies was the most toxic dioxin congener, 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) (Gasiewicz and Henry 2011, Okey 2007). 
Dioxins are widely present in the environment, and humans are also exposed to 
small amounts of them, mainly via food (Malisch and Kotz 2014, Travis and 
Hattemer-Frey 1991). There have additionally been several major accidental 
industrial releases, exposing populations to large quantities. The toxicological risk 
assessment of dioxins is based on increasing knowledge of their chemical properties 
and biological effects. Risk assessment has led to risk management measures, which 
aim to restrict human exposure and further industrial emissions into the 
environment. In addition, recommendations for risk groups have been given in order 
to limit the consumption of foodstuffs with high dioxin levels, such as certain Baltic 
Sea fish (Finnish Food Safety Authority Evira 2017). It is also now commonplace in 
many countries to monitor dioxin levels in food and livestock feed to detect cases of 
accidental contamination. Due to these actions, human exposure to dioxins has been 
declining (Malisch and Kotz 2014, Scientific Committee on Food 2000). 
However, human dietary exposure to dioxins remains close to the European 
tolerable weekly intake value, which denotes an estimate of the amount of dioxins 
humans can be exposed to throughout their lives without substantial health risks 
(Bilau et al. 2008, Kiviranta et al. 2004, Scientific Committee on Food 2001). 
Furthermore, dioxins are chemically extremely persistent, and will continue to be 
present in the environment. They are also highly hydrophobic and thus accumulate 
in the food chain (H. Geyer et al. 1986, H. J. Geyer et al. 1986). Therefore humans 
will be at risk of exposure to them also in the future (Malisch and Kotz 2014). 
However, our understanding of the adverse outcome pathways leading to dioxin 
toxicity, as well as of the health hazards they pose for humans in general, remain 
surprisingly incomplete, despite long-term research efforts and advancements made 
thus far. This is in large part due to the complexity of AHR functioning. In addition, 
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there is considerable variation in the effects of dioxins depending on, for instance, the 
species, strain, sex, age, developmental stage and organ in question (Pohjanvirta and 
Tuomisto 1994, Poland and Knutson 1982). Therefore, to better understand dioxin 
effects in humans, the need to increase our understanding of the molecular 
mechanisms underlying AHR-mediated toxicity remains. 
Insight into these mechanisms will also contribute to the study of physiological 
functions of the AHR, where research interest has more recently expanded. This has 
been a natural consequence of the evidence that the protein is evolutionarily ancient, 
apparently over 600 million years old (Hahn and Karchner 2011). Characteristically, 
such evidence suggests paramount importance in the biology of organisms. Indeed, 
AHR homologues are widespread across vertebrates, and are found in most of their 
cell types. They have also been found in invertebrates, but, interestingly, do not 
appear to bind TCDD in them (Butler et al. 2001, Hahn 2002). Therefore, the notion 
that in addition to mediating dioxin toxicity, the AHR could also have important 
physiological functions in vertebrates has become apparent. This hypothesis already 
stands confirmed, and the AHR has been shown to be important in normal 
development and health, although we are only beginning to discover and understand 
its varied physiological roles. 
One example of a seemingly AHR-related, protective physiological consequence is 
its involvement in novel food avoidance. This bizarre and intriguing, very sensitive 
effect has previously been characterised after low, well below acutely toxic doses of 
TCDD in rats and mice (Lensu et al. 2011b, J. T. Tuomisto et al. 2000). So far, it 
remains to be established whether the effect is specific to TCDD alone or a result of 
more general AHR activation. 
Further elucidating the many roles and mechanisms of the AHR in normal 
physiology as well as in toxicity will not merely be important in order to increase our 
knowledge and improve the accuracy of human health risk assessment. It will also 
conceivably aid in understanding the pathogenesis of AHR-related maladies and in 
the development of novel therapeutics for them. Regarding the latter, selective AHR 
modulators (SAHRMs) appear particularly interesting lead compounds. They 
modulate AHR activity by only eliciting a subset of the effects imparted by the 
receptor, often without causing the marked toxicity of dioxins. SAHRMs also have 
potential as important research tools in studying the molecular mechanisms of AHR 
function and are thus under intense scrutiny. 
In this thesis research, experimental in vivo and in vitro models were first 
employed to characterise the toxicological effects of two such novel SAHRMs. One of 
these compounds was then used, along with other AHR activators, to further examine 
the peculiar novel food avoidance behaviour in rats. The hypothesis regarding this 
effect was that it is not only caused by TCDD, but that the AHR acts as a more general 
biological sensor of the environment, protecting organisms from further ingesting 
potentially harmful foods. The overall objective of these studies was to contribute to 
research on the physiological and toxicological roles of the AHR. 
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2 REVIEW OF THE LITERATURE 
2.1 The aryl hydrocarbon receptor (AHR) 
The AHR is an evolutionarily ancient, evidently over 600 million-year-old protein 
(Hahn and Karchner 2011). It is a ligand-activated transcription factor (Burbach et 
al. 1992, Ema et al. 1992) and thus a regulator of gene expression, which it can either 
promote or repress. The AHR was first identified in Alan Poland’s laboratory in the 
1970s (Poland et al. 1976). Even prior to that, its most toxic activator, TCDD, was a 
recognised environmental contaminant, and known to cause chloracne in humans in 
occupational settings (Gasiewicz and Henry 2011). However, the molecular basis or 
the mode of action for this toxic effect was unknown. The first hints about the 
existence of the AHR came through studies related to the xenobiotic metabolising 
enzyme CYP1A1, then called aryl hydrocarbon hydroxylase (AHH). It was known that 
aromatic hydrocarbons (chapter 2.2.1) induced the expression of AHH, and that while 
some mouse strains were very sensitive to this effect, others appeared resistant 
(Nebert and Gelboin 1969, Nebert and Bausserman 1970). Later, it was uncovered 
that TCDD was a much more potent inducer of AHH than the compounds previously 
studied, and that the differences between strains were due to differing structures of 
the receptor that mediates the effects of these compounds, the AHR. 
The AHR is renowned for mediating the toxic effects of numerous xenobiotics, but 
it has lately also been recognised as an indispensable regulator of normal physiology 
and health, particularly during development (Benedict et al. 2000, Fernandez-
Salguero et al. 1995, Fujii-Kuriyama and Kawajiri 2010, Harrill et al. 2013, Tijet et al. 
2006). Furthermore, completely new areas regarding AHR functioning are still being 
discovered. Although our understanding of the functions of this receptor has 
increased substantially since the 1970s, surprisingly many of the questions posed so 
far remain incompletely answered. Furthermore, as information regarding the 
functions and mechanisms of the AHR has increased, the picture has become 
increasingly complex. Our knowledge of the molecular pathways and their 
interactions continues to be limited, and the list of genes that the AHR regulates is 
also still expanding as research progresses. 
An additional complication in achieving a comprehensive understanding of the 
functions of this protein is that the effects of the AHR vary greatly among, for 
instance, species, strains, organs and developmental stages. Furthermore, the 
numerous chemically diverse AHR-modulating compounds induce drastically 
differing effects, even among the different tissues and cell types within an organism. 
One of the difficulties in understanding the underlying mechanisms is that the exact 
three-dimensional structure of the AHR remains to be established. In particular, 
detailed information on the spatial structure of the ligand-binding domain (LBD), as 
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well as the differences in this structure among different species and strains, will 
probably further help us to understand some of the molecular mechanisms of the 
AHR. 
The AHR is present in most cell types across vertebrates, including humans (Hahn 
and Karchner 2011). While, for instance, humans, rats and mice have one AHR gene, 
some other mammals have two, and other vertebrates may have up to five (Gasiewicz 
and Henry 2011, Hahn et al. 2017). Moreover, AHR homologues are also widely 
present in invertebrates such as the nematode C. elegans, the fruit fly D. 
melanogaster, clams and sea urchins (Hahn et al. 2017). Invertebrates appear to 
possess single AHR genes, but, interestingly, the corresponding protein receptors do 
not recognise TCDD or other dioxins (Gasiewicz and Henry 2011), and as such appear 
to have purely physiological functions in them. Although non-mammalian AHRs are 
an interesting area, only vertebrate and more specifically mammalian AHRs and their 
functions are further discussed here due to the scope of this study. For information 
on AHR functions in fish and birds, Simonich and Tanguay (2011) have written an 
excellent review, and Powell-Coffman and Qin (2011) likewise on AHR functions in 
invertebrates. 
2.1.1 AHR signalling and its regulation 
Although at present incompetently understood at the molecular level, AHR signalling 
appears to involve two distinct types of pathways: canonical and non-canonical. The 
canonical pathway is dependent on the AHR directly binding to DNA at AHR-
responsive elements [AHREs; also called dioxin-responsive elements (DREs) or 
xenobiotic-responsive elements (XREs)], and subsequent gene transcription. Non-
canonical pathways, of which there seem to be several, involve the AHR interacting 
with other transcription factors or pathways within cells. It is likely that differences 
in mechanistic steps related to the signalling pathways and their regulation are 
important for the diverse outcomes of AHR modulation (Bonati et al. 2017, Gasiewicz 
and Henry 2011). 
 
Canonical AHR-signalling pathway. The canonical, also known as the classical 
AHR pathway is the major AHR-signalling pathway and its best understood 
molecular mechanism. It was first described in connection with the induction of the 
xenobiotic metabolising enzyme CYP1A1 (Figure 1), but it is believed to represent a 
more general pattern (Q. Ma 2011). The canonical pathway encompasses activation 
of the AHR by ligand binding in the cytosol, and the activated AHR then moving into 
the nucleus. There, it pairs with a structurally related protein, aryl hydrocarbon 
receptor nuclear translocator (ARNT), and the AHR–ARNT complex subsequently 
attaches to AHREs in DNA. This leads to the recruitment of coactivators, 
rearrangement of chromatin and modulation of gene expression, either its activation 
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or repression. Although the canonical signalling pathway is generally quite well 
understood, many details, especially about its regulation, are still lacking. 
 
Figure 1. The canonical pathway of AHR signalling for the induction of the CYP1A1 
xenobiotic metabolising enzyme (Q. Ma 2011). In its inactive state, the AHR is 
located in the cytosol in association with the chaperone proteins HSP90, XAP2 
and p23. Binding of a ligand to the PASB domain elicits a transformation in the 
AHR structure, exposing a nuclear localisation sequence (NLS). The NLS is a 
dimerization interface for ARNT, and its exposure causes the AHR to translocate 
into the nucleus. There, it dimerizes with ARNT and sheds the cytosolic protein 
partners, transforming into a high-affinity DNA-binding form. The AHR–ARNT 
dimer then binds to the DNA at specific recognition sites called AHREs in the 
promoter region of the Cyp1a1 gene, eventually leading to induced transcription 
of CYP1A1 mRNA. 
Non-canonical AHR-signalling pathways. In addition to the canonical 
pathway, the AHR appears to act through several non-canonical pathways, which do 
not involve AHRE binding (Dere et al. 2011, Kinehara et al. 2008, Lo and Matthews 
2012). Instead, they consist of the ligand-activated AHR interacting with other 
molecules within cells (Denison and Faber 2017, Guyot et al. 2013). 
Several non-canonical pathways encompass crosstalk of the AHR with nuclear 
receptors and other transcription factors, such as the oestrogen receptor (ER) and 
nuclear factor kappa B (NF-κB), which is involved in the regulation of inflammatory 
pathways (Guyot et al. 2013, Ohtake et al. 2003, Patel et al. 2009, Vogel et al. 2007). 
An important example of such non-canonical signalling encompasses the AHR acting 
as a ligand-dependent E3 ubiquitin ligase (Ohtake and Kato 2011). Via this pathway, 
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the AHR regulates the degradation of proteins, such as the ER and β-catenin, through 
the ubiquitin-proteasome system. Along with other steroid hormone receptors, the 
ER is important, for instance, in sexual maturation, gestation, and development of 
hormone-related cancers. β-Catenin is vital in the canonical Wnt signal transduction 
cascade, which, in turn, is significant in physiology, particularly embryonic 
development and the pathogenesis of several diseases, including cancers (Clevers and 
Nusse 2012). 
Furthermore, instead of heterodimerising with ARNT, the ligand-activated AHR 
has also been shown to pair with other nuclear proteins, such as the NF-κB-associated 
RelB (Denison and Faber 2017, Guyot et al. 2013, Vogel et al. 2007) and Krüppel-like 
factor 6 (KLF6), which is a tumour suppressor (Wilson et al. 2013, Wright et al. 2017). 
These distinct dimers bind to DNA sequences separate from AHREs, and regulate the 
expression of unique gene patterns, subsequently leading to the non-canonical 
regulation of gene transcription. 
Non-canonical pathways also include highly complex and variable nongenomic 
routes, whereby ligand-activated AHR signalling is further controlled by 
phosphorylation via protein kinases (Guyot et al. 2013, Matsumura 2011). These 
pathways are rapid, even taking place within minutes of exposure to an AHR 
activator. Examples of molecules involved in these pathways include Ca2+, c-src and 
other tyrosine kinases, cAMP-dependent protein kinases (PKAs), ERK kinase, 
arachidonic acid and cytosolic phospholipase A2, reviewed extensively by Matsumara 
(2011). 
 
Regulation of AHR signalling. While the AHR is present in practically all 
mammalian tissues, its expression levels greatly differ among cell types, tissues and 
developmental stages (Harper et al. 2006). There must thus be fine-tuned 
mechanisms that regulate the expression of the AHR, which may also involve 
differential regulation of the AHR gene (Gasiewicz and Henry 2011). Sequencing of 
the mouse, rat and human AHR genes in the early 1990s already suggested multiple 
possible transcription factor binding sites (Eguchi et al. 1994, Garrison and Denison 
2000, Gasiewicz and Henry 2011, Mimura et al. 1994), indicating that the Ahr could 
be up- and down-regulated in several different ways. Although a lot still remains to 
be elucidated about the mechanisms regulating AHR expression, many agents have 
been found to be involved. In addition to endogenous and exogenous compounds, 
these include physiological molecules such as hormones, growth factors and 
cytokines, and different conditions within the organism, for instance hypoxia, cell 
density, cell differentiation, neoplastic transformation, the developmental stage and 
age (Harper et al. 2006). 
Several distinct, active mechanisms have been shown to control the negative 
feedback of AHR function, leading to its down-regulation. Many of these mechanisms 
entail autoregulation, i.e. involve regulatory genes whose expression is induced by 
ligand-activated AHR signalling, eventually down-regulating it. One of these is 
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Cyp1a1, further discussed in chapter 2.3.2 under Xenobiotic metabolising enzyme 
induction. Another example of such gene products is TCDD-inducible poly (ADP-
ribose) polymerase (TiPARP). This belongs to the family of PARP enzymes, which 
have important cellular roles in, for instance, DNA repair, cell proliferation and cell 
death (Q. Ma et al. 2001, Morales et al. 2014). TiPARP acts as a transcriptional 
repressor of the AHR and directly regulates AHR activity via ADP-ribosylation 
(MacPherson et al. 2013, Matthews 2017). Another down-regulator of the AHR is aryl 
hydrocarbon receptor repressor (AHRR), which is a bHLH-PAS family protein like 
the AHR, and also directly up-regulated by ligand-activated AHR (Baba et al. 2001, 
Gasiewicz and Henry 2011, Mimura et al. 1999). However, the mechanism by which 
it restricts AHR activity is poorly understood at present (Evans et al. 2008, Fujii-
Kuriyama and Kawajiri 2011). Furthermore, proteolytic degradation of the AHR 
occurs through ubiquitination, resulting in the disintegration of the AHR–ARNT 
complex and shortening of the half-life of activated AHR (Q. Ma and Baldwin 2000). 
2.1.2 Structure of the AHR 
Despite functionally resembling ligand-activated nuclear receptors, such as the ER, 
structurally the AHR belongs to another subfamily of transcription factors called the 
basic helix-loop-helix/PER-ARNT-SIM proteins (bHLH-PAS). The bHLH-PAS 
family includes proteins that are involved in many physiological and developmental 
processes. These are particularly related to the sensing of and response to 
environmental and cellular signals, such as xenobiotics, hypoxia, circadian rhythms, 
appetite control, neurogenesis and synapse formation (Furness et al. 2007, Gasiewicz 
and Henry 2011, Gu et al. 2000). Several members of the family are also linked to 
human diseases, most consistently to cancer, but also, for instance, to metabolic 
syndromes and psychiatric conditions (Bersten et al. 2013, Wu and Rastinejad 2017). 
In addition to the AHR, so far only one other member of the family (hypoxia-inducible 
factor 1α) has been shown to bind and be activated by small-molecule ligands (Wu 
and Rastinejad 2017). However, a considerable amount remains to be learned about 
the bHLH-PAS family, and there is good reason to hypothesize that other members 
also bind ligands, which would make the family a new and interesting target for 
pharmacological research. 
The mouse, rat and human AHRs contain ~800–850 amino acids. Like other 
bHLH-PAS proteins, the structure of the AHR (Figure 2) includes an amino-terminal 
with a bHLH domain and two PAS domains, A and B, all of which are evolutionarily 
relatively conserved among species (Bonati et al. 2017, Gasiewicz and Henry 2011, Gu 
et al. 2000). The bHLH domain participates in dimerization with ARNT in the 
nucleus, which is essential for the ability of the ligand-activated AHR to bind to 
AHREs in DNA, and to induce transactivation (Hoffman et al. 1991, H. Ko et al. 1996, 
Reyes et al. 1992). In addition, bHLH is responsible for DNA binding. The two PAS 
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domains form a generic three-dimensional fold capable of small-molecule binding 
and protein–protein interactions. These, especially PASB, are responsible for ligand 
binding (Pandini et al. 2007) and interactions with cellular chaperones, such as the 
90-kDa heat shock protein (Hsp90), which is crucial for conformational stability of 
the cytosolic AHR (Murray and Perdew 2011). In addition, the PAS domains 
participate with bHLH in the dimerization of the AHR with ARNT, and DNA binding 
once the AHR–ARNT complex has been formed. 
The transactivation domain at the carboxyl-terminal is significant in target gene 
regulation and therefore signal transduction, and is generally quite poorly conserved 
and variable among species (Dolwick et al. 1993). 
 
Figure 2. Major domain structures of the AHR, and approximate locations of binding 
regions. Modified from (Q. Ma 2011) according to (Bonati et al. 2017). 
Even small changes in the structure of the AHR can give rise to differing ligand 
binding affinities, which may impact on subsequent AHR functioning. Within the 
LBD, the amino acid residues of the ligand-binding pocket can be responsible for the 
differences in binding. For instance, a sensitive and a resistant mouse strain 
(C57BL/6 and DBA/2J, respectively) with an approximately ten-fold difference in 
TCDD-binding affinity were reported to differ from each other by merely a single 
mutation within the LBD, resulting in one amino acid (Ala) turning into another (Val) 
in the resistant strain (Ema et al. 1994, Okey et al. 1989). Furthermore, as in the 
resistant DBA/2J mice, in the human AHR the corresponding amino acid is also Val, 
which is consistent with the view that humans are relatively resistant to the effects of 
TCDD (further discussed in chapter 2.3.1.2). Moreover, in the human LBD, a 
mutation turning this Val into Asp completely abolishes its ligand-binding activity 
(Ema et al. 1994). 
Variability in the transactivation domain at the C-terminal of the AHR may also 
help explain some of the differences seen between and within species. In rats, a 1000-
fold difference exists between two different strains in the TCDD doses required to 
elicit certain responses (Pohjanvirta et al. 2011). This is due to a single point mutation 
at the beginning of intron 10 of a TCDD-resistant Han-Wistar (Kuopio; H/W) strain, 
and consequent disruption of the normal exon–intron junction, leading to altered 
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mRNA splicing producing two unique AHR variants, a total loss of about 40 amino 
acids at the protein level, and altered transactivation domain structures (Pohjanvirta 
et al. 1998).  
The only AHR domain whose complete structure has been experimentally 
determined thus far is PAS-A (Wu et al. 2013). The 3D crystal or NMR structures of 
the other functional domains are lacking, including the structure of the AHR LBD, 
PAS-B. However, in silico models have been developed based on existing structural 
information from homologous systems and sequence alignment (Bonati et al. 2017, 
DeGroot et al. 2011). They allow predictions of the structures and properties of the 
functional domains, which can then be experimentally tested, for instance, by 
mutagenesis and functional analysis. 
2.2 AHR modulators 
Unlike many other ligand-activated transcription factors, the AHR is notably 
promiscuous and binds a large variety of ligands with diverse structures, and of both 
exogenous and endogenous origin. This promiscuity is considered to be at least partly 
due to differences in binding to the LBD (DeGroot et al. 2011). Furthermore, it is 
particularly interesting because the effects of AHR modulation are ligand specific 
(Denison and Faber 2017) and of great variety, ranging from beneficial to toxic. 
AHR modulators can either be full or partial agonists that activate, or antagonists 
that inactivate the receptor. In addition to these ligands, which exert their effects 
through binding with the AHR, there are also compounds that activate the AHR 
signalling pathway without directly binding to the receptor (Ledirac et al. 1997, Lesca 
et al. 1995). This can ensue, for instance, through the inhibition of AHR-mediated 
degradation of endogenous AHR agonists, leading to sustained secondary AHR 
activation (Wincent et al. 2012). 
2.2.1 Xenobiotic modulators 
AHR-modulating xenobiotic compounds are ubiquitous in our environment, and we 
are constantly exposed to them. Many are toxic to various degrees, while others are 
harmless or even beneficial to health. Xenobiotic AHR modulators belong to vastly 
different chemical groups and have diverse structures. They include, for instance, 
environmental contaminants, dietary compounds and manufactured products, such 
as chemicals and pharmaceuticals. 
The best known and most studied role of the AHR so far is its indispensable 
involvement in the mechanisms of toxicity of a group of environmental contaminants 
encompassing halogenated organic compounds. Of these, dioxins and structurally 
related compounds, such as polycyclic aromatic hydrocarbons (PAHs), are 
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particularly important due to their toxicity and widespread distribution in the 
environment. 
 
Dioxins and dioxin-like activators. Dioxins and dioxin-like compounds are 
environmental contaminants. They are subgroups of the highly toxic persistent 
organic pollutants (POPs), whose manufacture and use has been restricted by the 
international community since the beginning of 2000s, with the aim of banning them 
worldwide. Dioxins and dioxin-like compounds are distributed all around the world, 
and are predominantly found in soils and sediments. Furthermore, they can enter the 
food chain, where they biomagnify. 
The subgroups of dioxins and dioxin-like AHR-activating ligands can be further 
divided into polychlorinated dibenzodioxins (PCDDs; dioxins), polychlorinated 
dibenzofurans (PCDFs; furans) and polychlorinated biphenyls (PCBs), depicted in 
Figure 3. Each of these three groups consists of many compounds that have the same 
general structure but include a different number of chlorine substituents at different 
positions. Compounds that differ in both the total number and position of the chlorine 
substituents, representing all possible PCDD, PCDF or PCB compounds, are called 
congeners. The toxicity of different congeners greatly differs depending on their 
chemical structure, ultimately resulting in differences in AHR-binding affinities and 
pharmacokinetics (Safe 1990). 
 
Figure 3. Chemical structures of polychlorinated dibenzodioxins (PCDDs), the most potent 
dioxin congener 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), polychlorinated 
dibenzofurans (PCDFs) and polychlorinated biphenyls (PCBs). 
PCDDs include 75 congeners, of which 7 are particularly toxic, and PCDFs include 135 
congeners, 10 of which have dioxin-like properties. Both general structures may 
contain up to eight chlorine substituents. The congeners that result in characteristic 
dioxin-like toxicity have four to eight chlorine substituents, four of which are 
positioned in the lateral positions 2, 3, 7 and 8 (Safe 1990). PCBs exist as 209 
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congeners, a dozen of which are AHR agonists and considered dioxin-like due to their 
toxicity. This results from their structure, with a minimum of four chlorine 
substituents that are positioned co-planarly, rendering these compounds as rigid 
structures that are similar to PCDDs and PCDFs. Collectively, the 29 particularly toxic 
PCDD, PCDF and PCB congeners are often referred to as “dioxins”. 
The most toxic congener is TCDD (Figure 3), which is considered the most toxic 
synthetic chemical ever produced, based on its lethality in the most sensitive species, 
the guinea pig [LD50 ~1 μg/kg, (Schwetz et al. 1973)]. TCDD is a PCDD with four 
chlorine atoms in the above-mentioned positions. It has, as such, been widely 
employed in research as the classical compound for activation of the AHR, and a 
model compound for dioxin toxicity (further described in chapter 2.3.1.1). 
 
PCBs were previously widely manufactured and used in industry, mostly as mixtures, 
due to their non-flammability, chemical stability, high boiling point and electrical 
insulating properties. PCDDs and PCDFs, however, have never been manufactured 
deliberately, apart from research use. Nevertheless, they are easily formed 
unintentionally as by-products of industrial processes, including chlorine bleaching 
of paper pulp, smelting and the manufacture of chlorinated chemicals, and also due 
to incomplete combustion, for instance from uncontrolled waste incineration. In 
addition, PCDDs and PCDFs occur as impurities among other chlorinated chemicals, 
such as PCBs and chlorophenols.  
All of these compounds are chemically highly stable and resistant to 
biodegradation, which leads to their persistence in the environment. In addition, they 
are highly hydrophobic and accumulate in the food chain, and eventually also in 
humans (Kiviranta, et al. 2002, Travis and Hattemer-Frey 1991). Their half-lives in 
adult humans ranges up to 13 years (Milbrath et al. 2009). Dietary sources of dioxins 
are mainly fatty animal products, typically dairy products, eggs, meat and fish (J. 
Tuomisto et al. 2011). 
 
Polycyclic aromatic hydrocarbons (PAHs). PAH compounds naturally occur in 
coal, crude oil and gasoline. They are also produced in the burning of, for instance, 
coal, oil, gas, wood, garbage and tobacco. In addition, cooking of food, particularly 
meat, at high temperatures produces PAHs.  Like dioxins, PAHs are AHR ligands and 
several are commonly employed as AHR activators in research. A representative 
example is benzo-a-pyrene (BaP; Figure 4), a carcinogen that humans are typically 
exposed to from tobacco smoke and residential wood burning. 
While not a PAH compound due to the two oxygen molecules in its structure, β-
naphthoflavone (BNF; Figure 4) is another potent AHR agonist commonly used in 
research. It is a polyaromatic, PAH-type inducer of the AHR. 
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Figure 4. The chemical structures of the AHR agonists benzo-a-pyrene (BaP) and β-
naphthoflavone (BNF), which are commonly used in research. 
Dietary AHR modulators. In addition to the AHR-activating chemical 
contaminants in food, such as dioxins and PAHs, many naturally occurring AHR-
modulating compounds are also present in the human diet. They are commonly found 
in vegetables, fruits, berries, tea and herbal food extracts such as ginseng, gingko 
balboa and liquorice (Safe et al. 2011). Dietary AHR modulators can exhibit either 
AHR-activating or -inactivating properties, and several are partial agonists. In 
addition, many appear to be SAHRMs (further described below), exhibiting differing 
activities depending on, for instance, the exposure time, cell type and species (Safe et 
al. 2011, Van der Heiden et al. 2009). 
Among the major sources of AHR modulators in the human diet are polyphenolics 
(Gasiewicz and Henry 2011). Flavonoids are a large family of polyphenolic 
compounds that are widely present in vegetables and generally consumed in 
significant amounts (González et al. 2011). They have anti-inflammatory activity, and 
many are antioxidants. Examples of AHR-modulating flavonoids include 
debenzoylmethane, a constituent of liquorice, and several compounds found in green 
and black tea (Safe et al. 2011). Other types of AHR-modulating polyphenols, 
structurally loosely related to flavonoids, include curcumin, an anticancer compound 
found in turmeric spice (Aggarwal et al. 2003), and resveratrol, found in many fruits 
and berries, and in particular abundance in red grapes (González et al. 2011, Safe et 
al. 2011). Resveratrol has been extensively studied due to its wide array of protective 
effects, including strong antioxidant, anti-inflammatory, and anticancer properties 
(M. Jang et al. 1997). 
Several AHR-binding dietary compounds have been associated with health 
benefits (Safe et al. 2011). For instance, indole-3-carbinol (I3C), present in 
cruciferous vegetables such as cabbage and broccoli, and its several AHR-modulating 
metabolites arising in vivo, have been linked with the antitumorigenic activity of 
these vegetables (Bjeldanes et al. 1991, Chen et al. 1996, Chen et al. 1998). Also 
resveratrol has been shown to inhibit PAH-initiated tumorigenicity in vivo (M. Jang 
et al. 1997). Furthermore, it appears to prevent TCDD-induced developmental 
toxicity in mice, including cleft palate, renal pelvic dilation, and ureteric dilatation 
and tortuosity (J. Y. Jang et al. 2008, Safe et al. 2011), thus acting as an AHR 
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antagonist. On the other hand, in the mouse model for studying multiple sclerosis 
[MS; experimental autoimmune encephalomyelitis (EAE) model], resveratrol 
exhibits AHR-inducing activity, showing a protective effect similar to that of TCDD, 
and thus also agonistic activity (Quintana et al. 2008, N. P. Singh et al. 2007). 
Dietary AHR modulators characteristically have numerous cellular targets in the 
body, the AHR being only one of them. Furthermore, most of these compounds have 
only low to moderate AHR-binding affinities and CYP1A1-inducing potencies, 
typically >100 to 1000 times lower than that of TCDD (Safe et al. 2011). They are 
therefore unlikely to be highly important as physiological AHR ligands individually 
(Gasiewicz and Henry 2011). However, considering that small amounts of many of 
these compounds are constantly present in our diet, it is conceivable that they could 
have additive AHR-mediated effects. 
 
AHR antagonists and partial agonists. In addition to compounds that activate 
the AHR, there are compounds that bind to the AHR without causing effects, and are 
able to block or reduce the effects of AHR agonists, called AHR antagonists (Gasiewicz 
and Henry 2011, Keys et al. 1986). Most AHR antagonists compete with agonists for 
the same binding site, but several other mechanisms exist (Gasiewicz and Henry 2011, 
Henry et al. 1999, Nishiumi et al. 2007, Palermo et al. 2005). Examples of AHR 
antagonists include CH-223191 and GNF351, depicted in Figure 5. 
CH-223191 is a potent, ligand-selective inhibitor of AHR activation in various 
species (S. -. Kim et al. 2006, Zhao et al. 2010). It has been shown in vitro to block 
the binding of TCDD to the AHR, to inhibit its nuclear translocation and binding to 
AHREs, and to inhibit xenobiotic metabolising enzyme induction by TCDD (S. -. Kim 
et al. 2006). Furthermore, in vivo, in addition to significantly reducing the TCDD-
induced induction of xenobiotic metabolising enzymes, CH-223191 was shown by 
Kim and colleagues to prevent liver toxicity and wasting syndrome in mice. Moreover, 
CH-223191 appears to be a competitive, pure AHR antagonist with no detectable 
AHR-agonist activity. However, it has been shown to be ligand selective, fully 
antagonising only halogenated aromatic hydrocarbons, such as TCDD and PCBs, but 
not non-halogenated AHR agonists, such as PAHs, BNF or flavonoids (Zhao et al. 
2010). 
GNF351 has also been reported to be a competitive, complete AHR antagonist in 
vitro (Smith et al. 2011). It was demonstrated to be a potent, high-affinity ligand of 
the AHR, and to also be able to antagonise AHR activity related to both canonical and 
cytokine-mediated non-canonical signalling. Furthermore, GNF351 appears to be a 
non-selective antagonist. However, following oral exposure in vivo, the antagonising 
effect of GNF351 was limited to the gastrointestinal tract in mice (Fang et al. 2014). 
This was reported to be due to poor absorption and extensive metabolism. 
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Figure 5. Chemical structures of the AHR antagonists CH-223191 and GNF351. 
Not all AHR-modulating compounds are either agonists or antagonists; partial AHR 
agonists can act as both, depending on their concentration. In fact, most, if not all, of 
the early compounds employed as AHR antagonists, such as α-naphthoflavone, have 
later been discovered to be partial AHR agonists (Safe et al. 2011). The maximum 
efficacy of partial agonists is less than that of full agonists, and in the presence of a 
full agonist, partial agonists typically block or reduce the agonist’s effect by 
competitive binding. Partial AHR agonists are relatively common, for instance, 
among AHR modulators in the diet. 
Moreover, AHR-modulating compounds exist that can act as antagonists in some 
species and as agonists in others. This is most likely, at least in part, due to structural 
differences in AHR orthologues among species (Aarts et al. 1995, Gasiewicz and 
Henry 2011, Henry and Gasiewicz 2008). Furthermore, even within a single species, 
these compounds can have either or both agonist/antagonist activity, depending on 
the tissue. Such compounds are called selective AHR modulators (SAHRMs). 
 
Selective AHR modulators (SAHRMs). The term SAHRM has not been 
unambiguously defined, but it is generally used to describe compounds that exhibit 
tissue- or species-specific AHR activation or inactivation, or only induce some of the 
typical responses of AHR activation, but not others. The term is sometimes also used 
more specifically to describe compounds that exhibit AHR-mediated effects, such as 
anti-inflammatory properties, solely through non-canonical signalling pathways 
(Murray et al. 2010, Murray et al. 2011). SAHRMs may be naturally occurring 
compounds or engineered and optimised with the aim of inducing only favourable 
responses of AHR modulation.  
Considering the increasing evidence for involvement of the AHR in physiological 
functions and disease aetiology, including both pro- and antitumour pathways, it 
appears a highly interesting target for novel therapies employing SAHRMs. The 
rationale for this is based on the notion that some of the biological impacts of even 
TCDD are such that they would be beneficial in the treatment of certain diseases if 
they could be separated from the toxicity. These impacts are particularly related to 
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immunomodulation and cancer (Quintana et al. 2010, Vorderstrasse and Lawrence 
2006, Xu et al. 2015, Zhu et al. 2014). Therefore, in addition to cancer (Díaz-Díaz et 
al. 2016, Jin, Lee, Pfent et al. 2014), appropriate activation of the AHR could lead to 
novel therapeutics for the treatment of, for instance, MS (Quintana et al. 2010, N. P. 
Singh et al. 2007), inflammatory skin diseases (Di Meglio et al. 2014, Haas et al. 2016, 
Van Den Bogaard et al. 2013), Crohn’s disease (Benson and Shepherd 2011) and 
inflammatory bowel disease (Arsenescu et al. 2011, Furumatsu et al. 2011). In 
addition, SAHRMs can be useful tools in the quest of further elucidating the 
molecular mechanisms at play in the biological and toxicological roles of the AHR. 
The exact mechanisms of SAHRMs in tissue specificity are yet to be elucidated, 
but it is conceivable that they could resemble those of selective modulators of nuclear 
receptors, which exhibit a similar function as transcription factors to the AHR. For 
hormone-binding nuclear receptors, such as the ER, distinct mechanisms for 
selectivity have been established. These are due to multiple factors, including a) 
differential metabolism of ligands among different tissues, b) multiple receptor 
forms, splice variants, and differential patterns of receptor dimerization, in part 
depending on the ligand, and c) differences in the conformational changes of the 
receptor, and in the subsequent interactions with nuclear cofactors, depending on the 
ligand and/or tissue (Katzenellenbogen et al. 1996, Safe et al. 2013). 
A representative example of SAHRMs is one of the early engineered compounds, 
6-methyl-1,3,8-trichlorodibenzofuran (MCDF; Figure 6). MCDF binds to the AHR, 
but they form a complex that is transcriptionally inactive. Furthermore, MCDF has 
been shown to inhibit the induction of the xenobiotic metabolising enzyme CYP1A1 
by TCDD both in vitro and in vivo, and also to inhibit several classical TCDD-induced 
toxic responses, such as immunotoxicity and developmental toxicity (Astroff et al. 
1988, Bannister et al. 1989, M. Harris et al. 1989, Safe et al. 2011). Thus, MCDF 
clearly exhibits AHR-antagonistic activity. 
However, MCDF does not inhibit TCDD-induced, AHR-mediated antioestrogenic 
activity (described further under Carcinogenicity in chapter 2.3.1.1). In contrast, it 
acts as an AHR agonist in multiple oestrogen-responsive tissues in several species, 
showing antioestrogenic activity much like TCDD (Astroff and Safe 1991, Safe et al. 
2011, Zachrewski et al. 1992). This is interesting, because antioestrogenic compounds 
can be used in the treatment of hormone-dependent tumours, which are 
characteristic of, for instance, ER-positive breast cancer (Lerner and Jordan 1990). 
Correspondingly, MCDF has been shown to be a potent inhibitor of carcinogen-
induced mammary tumour growth in rats (McDougal et al. 1997). It has also been 
reported to inhibit prostate tumour metastasis in a mouse model (Fritz et al. 2009). 
In addition to MCDF, other SAHRMs have also been shown to inhibit the growth of 
hormone-dependent cancers, apparently without AHR-related toxicity (McDougal et 
al. 2001, Safe et al. 2011, S. Zhang et al. 2009). 
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Figure 6. Chemical structure of SAHRM 6-methyl-1,3,8-trichlorodibenzofuran (MCDF). 
Pharmaceuticals. Many drug targets are ligand-activated proteins, for instance G 
protein-coupled receptors or nuclear receptors. However, for a long time, the AHR 
was not seen as a potential drug target due to the view that AHR activation would 
inevitably lead to toxic consequences. Subsequently, this view has been overturned, 
and the AHR is presently seen as a highly potential drug target. Furthermore, there 
are in fact several existing drugs on the market that, while primarily modulating other 
pathways, have also been found to affect AHR activity (Table 1). This is not surprising 
given the present literature illustrating the varied functions of the AHR in physiology 
within organisms. 
Table 1. Examples of AHR-active drug compounds on the market 
Compound Drug class Indication(s) References 
Flutamide Antiandrogens Prostate cancer (Koch et al. 2015) 
Itraconazole, 
Ketoconazole 
Antifungal drugs (azole 
derivatives) 
Fungal infections (Korashy, 
Shayeganpour et 
al. 2007, Korashy, 
Brocks et al. 
2007) 
Leflunomide Disease-modifying 
antirheumatoid drugs 
Rheumatoid arthritis, 
psoriatic arthritis 
(O'Donnell et al. 
2010) 
Mexiletine Antiarrhythmic drugs (non-
selective sodium channel 
blockers) 
Heart arrhythmias (Jin et al. 2012) 
Nimodipine Calcium channel blockers Prevention of cerebral 
vasospasm and ischemia 
following subarachnoid 
bleeding 
(Jin et al. 2012) 
Omeprazole Proton pump inhibitors Gastroesophageal reflux 
disease, peptic ulcer 
disease 
(Dzeletovic et al. 
1997, Quattrochi 
and Tukey 1993) 
Sulindac, 
Salicylamide 
Nonsteroidal anti-
inflammatory drugs
  
Pain and inflammation (Ciolino et al. 
2006, MacDonald 
et al. 2004) 
Transilast Antiallergic drugs Asthma, allergic rhinitis, 
atopic dermatitis 
(Prud'Homme et 
al. 2010) 
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Many of the AHR-modulating drug compounds on the market are SAHRMs (Jin et 
al. 2012). Several are anti-inflammatory compounds, but others have also been 
reported. An interesting example is 4-hydroxytamoxifen, one of the major active 
anticancer metabolites of the classical breast cancer drug tamoxifen, which is a 
selective ERα-antagonist. 4-Hydroxytamoxifen is currently under development as a 
product, and therefore not yet on the market as a distinct drug compound, but it has 
been extensively studied in conjunction with tamoxifen. In addition to exhibiting 
anti-cancer properties, 4-hydroxytamoxifen has been shown to be an AHR ligand that 
modulates its transcriptional activity (DuSell et al. 2010). Therefore, through a 
metabolite, the mechanism of action of tamoxifen also appears to involve the 
modulation of the AHR (Gasiewicz and Henry 2011). 
Furthermore, numerous compounds are being studied as potential AHR-
modulating drug compounds, primarily for the treatment of different cancers and 
inflammatory diseases (Ehrlich and Kerkvliet 2017, Safe et al. 2013, Safe et al. 2017). 
Among these compounds is laquinimod, for which C1, one of the novel SAHRMs 
studied in this thesis, is an N-hydrogen metabolite. Laquinimod has been studied in 
phase II/III clinical trials for efficacy and safety in the treatment of MS (Polman et al. 
2005, Thöne and Linker 2016) and Crohn’s disease (D'Haens et al. 2015), and is 
currently in phase II studies for the treatment of Huntington’s disease (Garcia-
Miralles et al. 2016). The mechanism of action of laquinimod is not yet fully 
elucidated, but it has been recognised as an immunomodulatory compound (Varrin-
Doyer et al. 2014), and the mode of action has been shown to be AHR dependent in 
the mouse EAE MS model (Berg et al. 2016, European Medicines Agency 2014, Kaye 
et al. 2016) 
 
2.2.2 Endogenous modulators 
In addition to being promiscuous in ligand binding, another aspect that distinguishes 
the AHR from many other ligand-activated transcription factors is that, despite 
research efforts, no single endogenous substance has thus far stood out as its primary 
physiological activator. However, due to the functions of the AHR in normal 
physiology (chapter 2.3.2), it seems apparent that there must be one or several major 
endogenous activators of the AHR. 
There is one particularly interesting candidate group of compounds: metabolites 
and/or photo-oxidation products of tryptophan. Tryptophan is an essential amino 
acid that is present in most dietary proteins. It is the precursor for several important 
compounds in the body, such as serotonin, melatonin and niacin. Further derivatives 
include other indole-based compounds, many of which are AHR ligands (Heath-
Pagliuso et al. 1998, Helferich and Denison 1991, A. Rannug et al. 1987). Of these, 6-
formylindolo(3,2-b)carbazole (FICZ; Figure 7) appears particularly interesting due to 
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its potency and exceptionally high affinity for the AHR, which are comparable to those 
of TCDD (A. Rannug et al. 1987, Wei et al. 1998, Wincent et al. 2009). Regardless of 
these characteristics, FICZ is not toxic. In contrast, FICZ has been shown to 
ameliorate asthma symptoms and inflammatory skin conditions, such as psoriasis, in 
mouse models (Di Meglio et al. 2014, Jeong et al. 2012).  
Another two noteworthy tryptophan-metabolite AHR ligands are kynurenine and 
kynurenic acid, which appear to be particularly important in promoting AHR-related 
carcinogenesis (DiNatale et al. 2010, Opitz et al. 2011). A potent, non-toxic agonist 
called 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), on 
the other hand, has anticancer properties (Henry et al. 2006, Song et al. 2002, K. 
Wang et al. 2013). ITE has also been reported to have other protective properties, 
including the potential amelioration of several autoimmune disorders, such as uveitis, 
colitis and MS (Goettel et al. 2016, Nugent et al. 2013, Quintana et al. 2010). Further 
endogenous AHR agonists and antagonists include bilirubin, biliverdin, 7-
ketocholesterol, prostaglandins and arachidonic acid derivatives (Gasiewicz and 
Henry 2011, Safe et al. 2011) 
 
Figure 7. Chemical structure of the endogenous AHR agonist 6-formylindolo(3,2-
b)carbazole (FICZ). 
2.3 AHR-mediated effects 
The AHR is noteworthy as a transcription factor due to the diversity of modulators it 
binds. Moreover, the vast and varied array of functions it has been shown to mediate 
in organisms, both toxicological and physiological, further increases its importance 
in biology. However, understanding AHR-mediated effects in full has proved 
challenging due to the complexity of its function on several levels. 
 
Differences among species and strains. While AHR homologues are 
widespread in fauna, their functions among species vary. The expression of certain 
genes, such as Cyp1a1, is consistently modulated by the AHR across species in 
response to AHR modulators (Denison and Faber 2017). However, there are also 
various genes whose expression differs significantly among species (Flaveny et al. 
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2010, Forgacs et al. 2013, Kovalova et al. 2017, Sun et al. 2004). Most strikingly, a 
difference of over 2000-fold in TCDD lethality has been reported between the most 
sensitive and resistant species (guinea pig and hamster, respectively), represented as 
LD50 values, which denote the doses estimated to kill 50% of animals in an acute 
toxicity study. For guinea pigs, the LD50 value is 0.6–2 Pg/kg (M. W. Harris et al. 
1973, McConnell et al. 1978, Schwetz et al. 1973), while for hamsters it is reported to 
be as high as ~5000 Pg/kg (Henck et al. 1981). 
Even within species, AHR-modulator effects can differ among strains. The largest 
within-species difference in sensitivity to TCDD has been reported in rats, in which a 
difference of at least a 1000-fold exists between the most sensitive and resistant 
strains described [LD50 values ranging from 10–20 to >9600 Pg/kg in Long-Evans 
(Turku/AB; L-E) and H/W (Kuopio) rats, respectively (Pohjanvirta et al. 1993, Unkila 
et al. 1994)]. 
The strain and species differences in dose-dependent sensitivity to given AHR 
modulators appear to be largely attributable to structural differences in the AHR 
(Denison et al. 2011, Gasiewicz and Henry 2011, Pohjanvirta et al. 2011, Romkes et 
al. 1987). As described in chapter 2.1.2, even small changes in the structure of the 
protein may give rise to differences in its ligand-binding ability and transactivation, 
and subsequently the effects the AHR mediates. However, structural differences may 
not be adequate to explain the diversity of AHR-mediated molecular responses 
observed within organisms among, for instance, cell types or organs, sexes, age 
groups, or developmental stages, which further complicates the overall picture. 
 
Differences among AHR modulators. There is vast diversity in AHR-mediated 
effects depending on which modulator is responsible for initiating them, as already 
established in chapter 2.2. Although the sensitivity to TCDD among species and 
strains correlates with differences in the structure of the LBD, and consequently 
binding affinity (Pohjanvirta et al. 2011), this is not the case with AHR modulators in 
general. For example, the endogenous tryptophan metabolite FICZ is not toxic, much 
unlike TCDD, even though FICZ binds to the AHR in vitro with even somewhat 
greater affinity than TCDD (Kd values of 0.07 and 0.48 nM, respectively) (A. Rannug 
et al. 1987, U. Rannug et al. 1995). The differences in effects following the binding of 
these two compounds are probably, at least in part, due to kinetics. The metabolism 
of FICZ is extensive and rapid in vivo (Bergander et al. 2003, Bergander et al. 2004), 
whereas TCDD has a very long half-life, consequently bringing about prolonged 
activation of the AHR (Abraham et al. 1988, Rose et al. 1976). It appears that kinetics 
is also more generally a major contributor to the effects that different compounds 
produce within organisms (Van den Berg et al. 1994). 
Moreover, it appears that different AHR ligands, and consequently signalling 
pathways, can regulate the expression of distinct gene patterns (Denison and Faber 
2017). For instance, the AHR has been shown to regulate two separate gene batteries 
in mice: those dependent on TCDD and those independent of it (Tijet et al. 2006). 
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This could reflect the two distinct outcomes of activation of the receptor: mediation 
of the toxic effects of xenobiotics (below), and the maintenance of normal 
physiological functions (chapter 2.3.2). 
2.3.1 Toxic effects mediated by the AHR 
AHR-mediated toxicity is presented here using TCDD as a model compound. This is 
partly due to the complexity of AHR functioning, but also because of the scope of this 
study. Furthermore, TCDD is the most toxic AHR activator, and has therefore been 
extensively used in studying AHR-mediated toxicity. 
The toxic effects following TCDD exposure are almost exclusively dependent on 
the AHR (Fernandez-Salguero et al. 1996, Harrill et al. 2016, Mimura et al. 1997, 
Nishimura et al. 2005, Vorderstrasse et al. 2001), and practically all of the so far 
elucidated toxicities entail canonical signalling (Bunger et al. 2003, Bunger et al. 
2008, Tijet et al. 2006). However, it is possible that there are yet to be established 
toxic effects of TCDD that involve the non-canonical pathways. Candidates are, for 
instance, effects that occur through epigenetic mechanisms. 
As with the details of AHR signalling in general, the pathways responsible for the 
toxic effects of TCDD are still incompletely understood. The current consensus is that 
the toxicity results from inappropriately sustained and untimely activation of the 
AHR (Bock and Köhle 2006, Denison et al. 2011). Furthermore, it appears clear that 
it is a consequence of simultaneous dysregulation of multiple genes and signalling 
pathways, and as such very complex (Gasiewicz and Henry 2011). For instance, there 
are hundreds of genes in different tissues whose expression has been reported to be 
modified by TCDD, and these genes differ among species (Boutros 2011). 
The differences in TCDD susceptibility among species and strains mostly appear 
to be due to differences in AHR structure (Ema et al. 1994, Korkalainen et al. 2000, 
Pohjanvirta et al. 1998). Differences among organs and developmental stages within 
species and strains, on the other hand, may reflect the TCDD susceptibility of 
particular tissues. Many of the affected organs, tissues and cells are those undergoing 
differentiation and proliferating quite rapidly, such as epithelial and mucosal tissues, 
skin (in humans), spermatozoa and the immune system (Merches et al. 2017, 
Mocarelli et al. 2011, Stockinger et al. 2014). This is consistent with findings of TCDD 
altering the cell cycle, patterns of cellular proliferation and differentiation, and cell–
cell communication (Gasiewicz and Henry 2011). Furthermore, in most cases, the 
embryo and foetus are much more susceptible to the toxicity of TCDD than adults 
(Bock and Köhle 2006). Additionally, in developing organisms, inter- and intra-
species variability in sensitivity to TCDD-induced lethality is much less pronounced 
than in adults, with a difference of only a10-fold even between the most sensitive and 
resistant species (Huuskonen et al. 1994, Kransler et al. 2007). 
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2.3.1.1 TCDD toxicity in experimental animals 
TCDD causes a multitude of adverse effects in laboratory animals, of which the rat 
and mouse are the most studied species. Characteristic toxic effects seen in one or 
both of these species include lethality, immunotoxicity, hepatotoxicity, endocrine 
disruption, developmental toxicity, reduced fertility and carcinogenicity (Pohjanvirta 
et al. 2011). Furthermore, TCDD has effects on epithelial and mucosal tissues, teeth 
and bones, cardiovascular health, and induces oxidative stress. Recent findings in 
rats, mice and zebrafish also imply that TCDD may induce transgenerational effects, 
such as reduced fertility (T. R. Baker et al. 2014, Bruner-Tran and Osteen 2011, 
Sanabria et al. 2016). A possible mechanism may be epigenetic modification of DNA 
(B. B. Baker et al. 2016, J. Ma et al. 2015, Manikkam et al. 2012), although further 
studies on the mechanism are warranted. Overall, it is important to note that most of 
the toxic effects of TCDD are species specific. Moreover, similarly to the toxic effects 
following chronic exposure, TCDD toxicity following a single exposure also emerges 
in a delayed fashion. 
It is noteworthy that even species and strains that are very resistant to the lethality 
of TCDD, such as the H/W (Kuopio) rat and hamster, still display other AHR-
dependent effects, much like sensitive species (Gasiewicz, Henry et al. 1986, 
Pohjanvirta et al. 1988, Pohjanvirta et al. 2011, Unkila et al. 1993). Based on the 
TCDD-sensitive L-E and TCDD-resistant H/W rat strain model of TCDD toxicity 
(Pohjanvirta et al. 2011), AHR-mediated effects can be classified as either type I or 
type II. Type I effects emerge at the same doses in both strains, while eliciting type II 
effects in H/W rats requires at least 100-fold higher doses than in L-E rats.  
Consequently, this means that type I effects are robust to structural variations in the 
AHR transactivation domain, and thereby represent more generic AHR-mediated 
impacts. 
Type I effects include the induction of xenobiotic metabolising enzymes, thymus 
atrophy, foetolethality, a derailed vitamin A status, hypercholesterolemia, and 
reduced plasma thyroxine and melatonin levels (Pohjanvirta et al. 2011). Type II 
effects include lethality, wasting syndrome, liver toxicity and tumour promotion. As 
a general rule, type II effects occur within species and strains at higher doses of TCDD 
than type I effects, although exceptions exist. 
 
Lethality and wasting syndrome. While the most resistant species and strains 
can tolerate TCDD doses of even several g/kg, lethality is seen in sensitive species and 
strains in the dose range of μg/kg. The pathogenesis of TCDD-related lethality 
continues to be largely unknown, but it appears predominantly due to body weight 
loss resulting from hypophagia, which can culminate in wasting syndrome (Kelling et 
al. 1985, Lindén et al. 2010, McConnell et al. 1978, Pohjanvirta et al. 2011, Schwetz 
et al. 1973).  
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Wasting syndrome is a condition seen in several species after TCDD exposure, 
particularly in the guinea pig and rat. It is characterised by a dramatic body weight 
loss of even more than 50%, leading to lethality, and further includes hepatotoxicity, 
hepatosteatosis and decreased gluconeogenesis (Lindén et al. 2010, Pohjanvirta and 
Tuomisto 1994). However, even at very high doses following a single dose, mortality 
is only seen 1−8 weeks post-exposure, depending on the dose and sensitivity of the 
species or strain (Lindén et al. 2010, Poland and Knutson 1982). Prior to that, body 
weight loss is progressive. Interestingly, among all AHR agonists, wasting syndrome 
has only been reported to be brought about by TCDD and related dioxins (Neal et al. 
1979, Pohjanvirta and Tuomisto 1994). 
 
Organ toxicity. Depending on the species, TCDD causes toxicity in several organs 
and tissues. Some of the major targets include the liver, thymus, testes, intestine and 
urinary tract (Pohjanvirta et al. 2011). 
Thymic atrophy is the only TCDD-induced toxic effect that affects practically all 
mammals in a consistent and uniform manner (Gupta et al. 1973, M. W. Harris et al. 
1973, Pohjanvirta and Tuomisto 1994, Poland and Knutson 1982). It mainly stems 
from the depletion of small immature cortical thymocytes (Vos et al. 1974) by a 
mechanism that may involve delayed maturation of T-lymphocyte precursors 
(Greenlee et al. 1985, Holladay et al. 1991), enhanced apoptosis (McConkey et al. 
1988) and impaired thymic seeding by prothymocytes (Fine et al. 1990). 
Hepatotoxic effects of TCDD include lesions in the liver (Kociba et al. 1978, 
Pohjanvirta et al. 1989, Vos et al. 1974), hepatocellular hypertrophy (Christian et al. 
1986), hepatic steatosis (J. H. Lee et al. 2010), jaundice (Gupta et al. 1973), the 
accumulation of biliverdin (Niittynen et al. 2003) and altered vitamin A homeostasis 
(Hoegberg et al. 2003, C. K. Schmidt et al. 2003). 
Even in adult rats, exposure to TCDD induces alterations in testis morphology and 
function, including testicular atrophy, reduced Leydig cell volume, a reduced number 
of spermatids and decreased spermatozoa number (Chahoud et al. 1992, El-Sabeawy 
et al. 1998, Johnson et al. 1992). In the stomach, intestine and urinary tract, epithelial 
and mucosal lesions are seen (McConnell et al. 1978, Poland and Knutson 1982). 
Furthermore, TCDD induces hypoglycaemia and alterations in blood lipids, including 
hypercholesterolemia and an elevation of free fatty acids (FFA) in plasma (Fletcher et 
al. 2005, Pohjanvirta et al. 1989, Potter et al. 1983, Simanainen et al. 2003). 
 
Immunotoxicity.  Even a single dose of TCDD weakens both cell-mediated and 
antibody-mediated adaptive immunity in rodents, increasing their susceptibility to 
infectious diseases and transplanted tumours (Kerkvliet 2011, Luebke et al. 2006, 
Pohjanvirta and Tuomisto 1994). Immunotoxicity occurs in mice in the range of low 
Pg/kg, below doses that induce overt toxicity (Kerkvliet 2011). Interestingly, TCDD-
induced immunotoxicity appears to be independent of thymus function, as 
thymectomised adult mice are also sensitive to dioxin-induced immune suppression, 
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which furthermore occurs at doses below those inducing thymic atrophy (Kerkvliet 
and Brauner 1987). 
 
Endocrine disruption. Particularly in the rat, TCDD causes disturbances of the 
hormone system (Pohjanvirta et al. 2011). These effects include decreases in the 
circulating levels of testosterone, insulin and melatonin, and an increase in the level 
of adrenocorticotropic hormone. The level of corticosterone, the main glucocorticoid 
in rats, is also modulated (Dibartolomeis et al. 1987). 
Furthermore, thyroid function is disturbed, manifested as a decrease in the 
circulating level of thyroxine (T4), which chiefly emanates from accelerated thyroxine 
catabolism by UGT1A6 in the liver (Nishimura et al. 2005). Furthermore, an increase 
in thyroid-stimulating hormone is induced (Potter et al. 1986). The reduction in 
serum thyroxine appears to be one of the most sensitive endocrine indicators of 
exposure to TCDD in adult rats, with an ED50 between 1 and 5 μg/kg in SD rats 
(Viluksela et al. 2004).  
 
Developmental toxicity. As previously mentioned, all species and strains are 
almost equally sensitive to TCDD lethality in the embryonic stage (Kransler et al. 
2007). Furthermore, developmental effects following TCDD exposure in utero are 
among the most sensitive endpoints overall, appearing at doses that are well below 
those that are toxic to the pregnant or lactating adult female (Abbott 2011). Effects 
observed in different species include foetal lethality, the inhibition of growth, effects 
on liver weight, neurobehavioural effects, endocrine disruption and malformations 
(Abbott 2011, Brouwer et al. 1995, Couture et al. 1990). However, the major 
developmental effects following TCDD exposure in utero largely depend on the 
species. 
In mice, hydronephrosis and cleft palate are the characteristic and most sensitive 
effects (Abbott 2011). In rats, typical developmental toxicity likewise entails cleft 
palate, effects on teeth and bone, and disturbances in male sexual behaviour and the 
reproductive system (Huuskonen et al. 1994, Kattainen et al. 2001, Mably, Moore, 
Goy et al. 1992, Mably, Moore and Peterson 1992). In particular, the effects on teeth, 
such as disturbances in molar development, are among the most sensitive endpoints 
in developing rats, but they also occur in many other species (Viluksela et al. 2011). 
 
Carcinogenicity. TCDD is a carcinogen in all experimental animal species tested, 
targeting, for instance, the liver, thyroid, lung, skin and oral cavity, depending on the 
species (Pohjanvirta et al. 2011, Schrenk and Chopra 2011). It is not genotoxic but 
also induces tumours after chronic treatment in the absence of tumour initiators 
(Kociba et al. 1978). In addition, TCDD acts as a tumour promoter (Pitot et al. 1980). 
The underlying mechanisms are at present mostly undefined, although at least three 
distinct ways have been recognised in which activation of the AHR can stimulate 
tumorigenesis: the metabolic activation of procarcinogenic compounds, modulation 
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of genes related to proliferation and the immune system, and regulation of apoptosis 
(Bersten et al. 2013, Schrenk and Chopra 2011). 
The metabolic activation of procarcinogens applies, for instance, for PAHs such 
as BaP, which are bioactivated into reactive metabolites that form DNA adducts 
(Nebert et al. 2004). These, in turn, bind covalently to DNA, resulting in mutations 
that may eventually lead to cancer. 
The AHR can also stimulate tumour promotion and/or progression through the 
modulation of genes that are related to proliferation and the immune system (Bersten 
et al. 2013). For example, in human gliomas, constitutive metabolism of tryptophan 
to kynurenine by tumour cells leads to AHR-mediated increased tumour-cell survival 
and motility, and the inhibition of antitumour immune responses via the suppression 
of the recruitment of tumour antigen recognizing immune cells (Opitz et al. 2011). 
This is associated with malignant progression and poor survival. 
Furthermore, the inhibition of apoptosis appears to be an important mechanism 
in AHR-mediated carcinogenesis (Schrenk and Chopra 2011), and may prove a more 
accurate explanation for the tumour promoting activity of TCDD than the induction 
of cell proliferation (Pääjarvi et al. 2005, Stinchcombe et al. 1995). The mechanisms 
behind the AHR-mediated inhibition of apoptosis are at present poorly understood, 
but p53 appears to be a key regulator (Pääjarvi et al. 2005, Schrenk and Chopra 2011). 
2.3.1.2 Dioxin toxicity in humans 
Throughout this chapter, the term “dioxins” is used to cover the 29 toxic PCDDs, 
PCDFs and dioxin-like PCBs discussed in chapter 2.2.1 under Dioxins and dioxin-like 
activators. 
 
Health effects of dioxins. Knowledge of the health effects of dioxins in humans is 
much less comprehensive than the information available from experimental animals. 
Epidemiological data that offer insights into the toxic effects in humans are mainly 
from populations that have been exposed to accidental, major industrial releases of 
dioxins. The largest release occurred in Seveso, Italy, in 1976, when an industrial plant 
exploded, releasing about 6 tonnes of various chemicals, including an estimated 2–
20 kg of TCDD. The most severely affected population comprised about 17 000 
people. In addition to the information from the Seveso and other, smaller 
epidemiological cohorts, there are also a few case reports of individuals and 
populations that have been exposed to particularly substantial amounts of TCDD and 
other dioxins due to accidents, occupational exposure or deliberate poisonings 
(Geusau et al. 2001, Guo et al. 2004, Masuda 2001, Sorg et al. 2009, S. -. Wang et al. 
2008). 
Unlike in many laboratory animal species, lethality has not been observed in 
humans, even after high exposures, and overall, humans appear relatively resistant to 
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the effects of dioxins (Aylward et al. 1996, Black et al. 2012). This is probably, at least 
in part, due to their relatively low binding affinity to the human AHR compared with 
rodents (Okey et al. 1994). The highest dose of TCDD measured in a human has been 
a calculated dose of 25 Pg/kg (Geusau et al. 2001). Initially, this individual exhibited 
nonspecific gastrointestinal symptoms, a moderate elevation of blood lipids, 
leukocytosis, anaemia and secondary amenorrhoea. The only marked toxic effect 
observed in up to two years of follow-up was severe, generalized chloracne, which is 
a skin disease and a characteristic adverse effect in humans after very high exposures 
to dioxins (Geusau et al. 2001, White et al. 2011). However, based on epidemiological 
data from the Seveso and other cohorts, other health effects following high exposures 
have been reported after an extended follow-up. 
With very high exposure levels, an association with an overall elevation in cancer 
risk has been established (White et al. 2011). The IARC has also classified TCDD as 
carcinogenic to humans (Group 1), while other dioxins have been categorised as not 
classifiable (Group 3) due to inadequate data (International Agency for Research on 
Cancer 1997). In addition to cancer, high doses of dioxins have been identified to have 
endocrine disrupting properties within sensitive time windows, and to cause 
developmental effects, such as an altered sex ratio of offspring, altered sperm quality 
and disturbances in the development of teeth, including hypomineralisation and 
hypodontia (Alaluusua et al. 1996, Alaluusua et al. 2004, Viluksela et al. 2011, White 
et al. 2011). 
Less evident, but still possible adverse health effects in humans include type 2 
diabetes and reproductive effects, for instance an increased risk of infertility. While 
effects on blood lipids, thyroid function and cardiovascular health are seen in 
experimental animals, the epidemiological data for these effects in humans remain 
conflicting. Also, based on the epidemiological data, it is unclear whether dioxins have 
immunological effects in humans. Some of the epidemiological cohorts are still being 
followed, and upcoming data may provide more information on these so far 
ambiguous effects. 
 
TEF/TEQ concept. In the environment, TCDD is always present in mixtures, and it 
is therefore not generally possible to directly assess its effects in humans. 
Furthermore, as dioxins are a group of structurally related but toxicologically 
different contaminants, their risk assessment should reflect this to be effective. 
Hence, instead of the assessment of individual congeners, a different approach is 
taken. Based on current knowledge of the compounds, a concept of toxic equivalency 
(TEQ) is used to report toxicity-weighed masses of dioxin mixtures (Van Den Berg et 
al. 1998). This allows a comparison of the toxicity of different congeners, as well as 
an assessment of their combined effects. 
The approach is based on the chemical structures and AHR-binding abilities of 
different congeners, their toxic potencies, persistence in the environment and 
accumulation within organisms and in the food chain, and the general consensus that 
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the toxic effects of dioxins are mediated by the AHR and are thus additive. Therefore, 
each dioxin congener has been assigned a toxic equivalency factor (TEF) by the World 
Health Organization (WHO) to reflect their toxicity in relation to that of TCDD (Van 
den Berg et al. 2006). TEFs are further used for the calculation of total mixture TEQs 
by multiplying the mass of each congener by its TEF, and then summing the result for 
all the congeners in a mixture. The TEFs undergo re-evaluations as additional data 
are obtained. However, it is recognized that while their use is generally accepted, 
TEFs are of necessity approximations based on incomplete data (Gasiewicz and 
Henry 2011) and this approach therefore has limitations. 
 
Risk assessment of dioxins. Food is the primary human source of dioxins, which 
are particularly present in fatty animal products such as dairy products, eggs and 
meat (Scientific Committee on Food 2000). This is typically a result of the 
bioaccumulation of dioxins in the food chain, but there have also been several cases 
of dioxin contamination in farmed animal feed, leading to the resulting foodstuffs 
containing high levels of dioxins. In the Nordic countries, the main source is fatty 
Baltic Sea fish, especially Baltic herring and salmon, which contain relatively high 
(although declining) concentrations of dioxins (Hallikainen et al. 2011). The risk 
groups for dioxin exposure are considered to be children and thus also women of 
childbearing age, due to susceptibility to the effects of dioxin during development. 
Excluding accidental exposures that are not typically relevant to the general public, 
the estimated average intake of dioxins in many countries is below 5 pg/kg BW/day 
(Bilau et al. 2008, Fromme et al. 2009, Safe et al. 2011). However, the amounts can 
be significantly higher for individuals consuming large quantities of products with 
high dioxin levels. 
The former European Commission Scientific Committee on Food set the tolerable 
weekly intake for dioxins at 14 pg WHO TEQ/kg BW (Scientific Committee on Food 
2001). The Joint Expert Committee on Food Additives of WHO and the UN Food and 
Agriculture Organisation similarly established a tolerable monthly intake at 70 pg/kg 
BW for dioxins (Joint FAO/WHO Expert Committee on Food Additives 2002). 
However, a more recent risk assessment by the US Environment Protection Agency 
concluded on a lower dose level, denoting an estimate of the likely lifelong safe 
exposure, at 0.7 pg/kg BW/day (United States Environmental Protection Agency 
2012). An updated risk assessment of dioxins by the European Food Safety Authority 
is currently in progress. 
A major problem with dioxin risk assessment is the large variation in dioxin effects 
between and within species, which complicates extrapolation from in vivo studies to 
human health hazard and risk assessment. This holds especially true without robust 
mechanistic information from each species.  Therefore, the need to better understand 
the molecular mechanisms of both physiological and dioxin-related AHR pathways, 
and differences among species and different developmental stages, is also valuable 
for risk assessment. 
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2.3.2 Physiological functions of the AHR 
The physiological functions of the AHR are far less understood than the dioxin-
induced toxicological effects. This is due to research efforts directed towards 
physiology having increased much later than those concerning the structure of the 
protein and its toxicological effects, where the research started. The lack of evident 
endogenous modulators further contributed to this. More recently, however, instead 
of considering the AHR as chiefly important in toxicology, the view has shifted 
towards seeing AHR-mediated toxicity as a result of over-expression or dysregulation 
of its primary physiological functions (Kung et al. 2009). 
Nonetheless, the notion that the AHR is likely to have physiological effects has 
prevailed almost as long as the receptor has been known to exist. One of the early 
findings in this field was that there are significant differences in the health, fertility 
and life span of mice that are differently sensitive to TCDD (Gasiewicz and Henry 
2011, Nebert et al. 1984, Nebert 1989). The mice that are more sensitive to TCDD, due 
to differences in the structure of their AHR homologue, and thus possess a “high-
affinity” receptor, have a longer life span than those that are more resistant and have 
a “low-affinity” receptor, implying that a properly functioning AHR is important for 
physiology. 
The development of several transgenic AHRKO mice models as well as mice with 
a constitutively active AHR have been important; they have provided evidence that 
the AHR is involved in numerous physiological functions (Table 2), even if the 
mechanisms are often currently incompletely understood. However, the different KO 
mouse strains display slightly differing phenotypes, and the phenotype of KO rats also 
differs from that of KO mice (Harrill et al. 2013, Lahvis and Bradfield 1998). 
The physiological function of the AHR that has been recognised longest and is 
understood in most detail is its participation in xenobiotic metabolism. Furthermore, 
it appears that the AHR has particularly important functions in foetal development 
and immunomodulation. 
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Table 2. Examples of the physiological functions of the AHR in rodents. 
Participates in Examples References 
Metabolism of 
xenobiotics 
Induction of phase I and II enzymes, e.g. 
cytochrome P450 (CYP) and UDP-
glucuronosyltransferase (UGT) enzymes 
Reviewed in (Köhle and 
Bock 2007) 
Development Cell differentiation (Casado et al. 2010, Van 
Den Bogaard et al. 2015) 
Foetal liver development 
Liver angiogenesis 
(Bunger et al. 2008, J. V. 
Schmidt et al. 1996) 
Reproduction Development and function of reproductive 
systems 
Regulation of female and male fertility 
Reviewed in (Karman et 
al. 2011) 
Cell growth Haematopoietic stem cell maintenance 
Regulation of the cell cycle 
Regulation of apoptosis 
(C. Ko and Puga 2017, 
Pääjarvi et al. 2005, Park 
et al. 2005, K. P. Singh et 
al. 2009) 
Immunomodulation 
(regulating immune 
and autoimmune 
function) 
Regulation of B and T cell development 
Induction of apoptosis in T cells in the EAE 
model (in concert with ER) 
(De Abrew et al. 2010, 
Esser et al. 2009, 
Quintana et al. 2008, N. P. 
Singh et al. 2007). 
Tumour suppression Reviewed in (Bersten et 
al. 2013, Fujii-Kuriyama 
and Kawajiri 2010) 
Maintenance of gastrointestinal homeostasis 
and protection against intestinal bacterial 
infections through innate lymphoid cells 
(Kiss et al. 2011, J. S. Lee 
et al. 2012) 
Sensing of bacterial virulence factors, 
controlling of antibacterial responses 
(Moura-Alves et al. 2014) 
Control of intestinal 
microbiota 
Moderation of host–microbiota communication Reviewed in (L. Zhang et 
al. 2017) 
Lipid metabolism Regulation of cholesterol synthesis 
Regulation of fatty acid synthesis 
(J. H. Lee et al. 2010, 
Tanos, Patel et al. 2012, 
Tanos, Murray et al. 2012) 
Energy balance Regulation of body weight (Moyer et al. 2016, Moyer 
et al. 2017, Pohjanvirta 
2017) 
 
 
 
Xenobiotic metabolising enzyme induction. Within organisms, the induction 
of xenobiotic metabolising enzymes is the most important mechanism by which the 
metabolism of xenobiotics is regulated. It is typically controlled by a diverse set of 
ligand-activated transcription factors, including the AHR and several nuclear 
receptors. As a consequence, the metabolism of chemicals, including drug 
compounds, is enhanced, which generally renders them easier to excrete from the 
body. Overall, an enhanced metabolic rate is mainly considered advantageous to an 
organism, as it augments its detoxification capacity (Nebert et al. 2004). However, 
the induction of metabolism may also lead to toxic consequences such as tissue 
damage or tumorigenesis. Mechanisms include the bioactivation of potentially 
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genotoxic xenobiotics such as PAHs, DNA adduct formation and the production of 
reactive oxygen species, which may consequently lead to oxidative DNA damage 
(Gasiewicz and Henry 2011, Shimada and Fujii-Kuriyama 2004). 
The AHR gene battery includes xenobiotic metabolising enzyme genes whose 
expression is induced through the activation of the AHR. They encode such enzymes 
as CYP1A1, CYP1A2, CYP1B1, glutathione S-transferase (GST) A1, NAD(P)H quinone 
dehydrogenase 1 (NQO1) and UDP-glucuronosyltransferase (UGT) 1A (Q. Ma 2011). 
Of these, the induced transcription of CYP1A1 mRNA is particularly noteworthy, as 
the molecular mechanism is well understood (Figure 1), and its induction is a fairly 
rapid and highly sensitive, although not strictly specific, marker for AHR activation 
(Abraham et al. 1988, Hu et al. 2007). Unlike what has been presumed for a long 
time, it appears that the induction of xenobiotic metabolising enzymes, such as 
CYP1A1, does not automatically indicate dioxin-like toxicity, or correlate with it (Hu 
et al. 2007, Pohjanvirta et al. 2011). For instance, AHR-mediated toxicity can be 
present when CYP1A1 expression has been eliminated (Carney et al. 2004), and 
substantial CYP1A1 induction can be observed without toxicity (Gasiewicz, Rucci et 
al. 1986). 
In addition to xenobiotic metabolism, an important function of the CYP1A1 
enzyme appears to be autoregulation of AHR activity via a feedback mechanism, 
attempting to ensure adequate expression of the AHR (Chiaro et al. 2007, Q. Ma 
2011). Disruption of this autoregulation may lead to toxic outcomes due to both 
insufficient CYP1A1 metabolism, which may lead to over-stimulation of the AHR, and 
over-expression of CYP1A1, eventually leading to AHR deficiency. 
Over-stimulation of the AHR can result, for instance, from the delayed 
metabolism of endogenous AHR-activators. Several of them, such as FICZ, are very 
potent, but have a short duration of action due to efficient metabolism, mainly by 
CYP1A1 (A. Rannug et al. 1987, Wei et al. 1998, Wei et al. 2000, Wincent et al. 2009). 
Thus, factors that inhibit CYP1A1 activity, such as certain metal ions, drug compounds 
and polyphenols, may prolong the effect of the endogenous AHR activators, resulting 
in increased (secondary) AHR activity (Wincent et al. 2012). On the other hand, 
prolonged expression of Cyp1a1 can deplete the reservoir of endogenous AHR ligands 
due to their exaggerated metabolism, resulting in an AHR-deficient-like state 
(Schiering et al. 2017). This has been shown by Schiering and colleagues to result in 
increased susceptibility to enteric infection due to the disrupted function of the 
immune system. Additional consequences of elevated CYP1A1 activity include 
changes in the metabolism of a variety of endogenous molecules with signalling 
properties, such as retinoids (Lampen et al. 2000, Shmarakov 2015), steroid 
hormones (Spink et al. 1992), and polyunsaturated fatty acids (Hankinson 2016). 
 
Immunomodulation. The AHR has been identified as part of the molecular 
pathways of physiological immune responses, and is thus also a target for 
immunomodulatory therapies (Zhu et al. 2014). The AHR is involved in both innate 
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and adaptive immunity, and has pro- and anti-inflammatory effects, although the 
mechanisms are not clearly understood at present (Stockinger et al. 2014). 
Furthermore, the AHR may be deeply involved in autoimmunity, as it is highly 
expressed in Th17 cells (Veldhoen et al. 2008), a subset of pro-inflammatory T helper 
cells that, among other functions, are important in the pathogenesis of autoimmune 
diseases (Zambrano-Zaragoza et al. 2014). Moreover, the AHR has been shown to 
regulate the differentiation of Th17 cells (Kimura et al. 2008, Quintana et al. 2008, 
Veldhoen et al. 2008).  
In addition to its immunotoxic effects, even TCDD also induces potentially 
beneficial modulation of the immune system, namely its suppression. This is 
manifested as the suppression of autoimmune diseases in animal models, including 
onset of type 1 diabetes (Kerkvliet et al. 2009), EAE (Quintana et al. 2008), and the 
lessening of allergic responses (Luebke et al. 2001, Schulz et al. 2013, Xu et al. 2015). 
In addition, immunomodulation through the activation of the AHR by other agonists 
has also been shown to diminish the severity of numerous inflammatory conditions, 
such as EAE (Quintana et al. 2010), colitis (Arsenescu et al. 2011, Benson and 
Shepherd 2011, Furumatsu et al. 2011, Goettel et al. 2016) and psoriasis (Di Meglio 
et al. 2014). Furthermore, the AHR has been shown to sense and bind distinct, 
pigmented bacterial virulence factors, and to subsequently control antibacterial 
responses (Moura-Alves et al. 2014). 
It has been proposed that non-canonical AHR signalling could be involved in these 
immunomodulatory processes, for instance through cross-talk with NF-κB signalling 
(Gasiewicz and Henry 2011, Matsumura 2009, Stockinger et al. 2014). Interestingly, 
several flavonoids and other types of polyphenols, some of which were described 
under Dietary AHR modulators in chapter 2.2.1, have also been shown to have 
significant anti-inflammatory activity (González et al. 2011). Furthermore, even 
though the group of polyphenols includes compounds of very diverse structures, their 
effects on inflammation appear highly consistent, involving, for instance, the 
inhibition of NF-κB signalling. 
 
Anti-tumorigenicity. Furthermore, it appears that the AHR can act in antitumour 
pathways (Bersten et al. 2013). As already briefly discussed in chapter 2.2.1 under 
Selective modulators (SAHRMs), AHR modulators can have protective, tumour-
suppressive properties, especially towards hormone-related cancers such as breast 
and prostate cancers. It was already reported in the 1970s that while increasing the 
incidence of some types of tumours, TCDD as a chronic treatment also seemed to 
protect female rats from spontaneous mammary gland and uterine tumour formation 
(Kociba et al. 1978). This appears to be related to crosstalk between the AHR and ER 
signalling pathways (Gasiewicz and Henry 2011, Safe and Wormke 2003). Activation 
of the AHR has later been shown to inhibit invasive and metastatic activities in both 
ER-dependent and -independent human breast cancer cell lines, and in breast cancer 
stem-like cells (Gasiewicz and Henry 2011, Hall et al. 2010, Prud'Homme et al. 2010). 
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There are further results, particularly from AHRKO mouse models, suggesting 
antitumorigenic roles for the AHR through several possible mechanisms (Bersten et 
al. 2013, Ohtake and Kato 2011), including antiproliferative regulation via non-
canonical signalling and anti-inflammatory mechanisms mediated by the AHR. As 
discussed in chapter 2.2.1 under Selective modulators (SAHRMs) and 
Pharmaceuticals, there are already compounds on the market used for anticancer 
therapy that have later also been shown to modulate AHR activity. 
2.4 TCDD and novel food avoidance behaviour 
One of the more peculiar responses to TCDD exposure observed in rats and mice is 
novel food avoidance behaviour. An originally fortuitous and unexpected finding 
revealed that low, well below acutely toxic doses of TCDD result in a strong and very 
persistent avoidance of previously unfamiliar foodstuffs when administered either 
simultaneously with or a short time before the introduction of the foods (Lensu et al. 
2011a, Lensu et al. 2011b, J. T. Tuomisto et al. 2000).  
Interestingly, the well-documented rat strain differences in sensitivity to TCDD 
are not reflected in susceptibility to this behaviour; both TCDD-sensitive 
and -resistant rat lines exhibit comparable avoidance behaviour (Lensu et al. 2011b). 
It is displayed towards different types of novel foodstuffs, including milk chocolate, 
cheese, and 10% sucrose and 0.25% saccharin solutions. Even a change in the texture 
of the standard feed (pelleted vs. powdered) has been found sufficient to induce the 
avoidance (Lensu et al. 2011a). Furthermore, unlike many other TCDD-induced 
effects, the avoidance response emerges rapidly, within hours of a single TCDD 
exposure coupled with the presentation of a novel food. Moreover, it emerges at very 
low doses of ≤ 1 μg/kg, in both TCDD-sensitive and -resistant rat lines (Lensu et al. 
2011b). Hence, this response is one of the most sensitive behavioural effects TCDD 
has been shown to exert in adult laboratory animals. 
The avoidance behaviour appears to closely resemble two behavioural 
phenomena: taste neophobia and conditioned taste avoidance (CTA; often also used 
interchangeably with the term conditioned taste aversion). Both of them occur in 
animals and humans alike. They are behavioural mechanisms that have been 
interpreted to have evolved to protect animals from eating potentially harmful food. 
It has also been suggested that taste neophobia and CTA can be intertwined, so that 
when suspicions of toxicity are aroused, the former mechanism primes the latter to 
become engaged and enhanced (Lin et al. 2016). 
 
Taste neophobia. Neophobia is considered an innate, protective behaviour that can 
be experienced towards food, but also novel objects or environments (Corey 1978). 
Taste neophobia is a novelty-induced fear response that prevents the ingestion of 
large amounts of novel foods, and typically subsides rapidly once the novelty becomes 
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familiar and is deemed safe. Like CTA, it appears to involve aversive behaviour, 
whereby the palatability of the novel food is initially reduced (Lin et al. 2012). Taste 
neophobia is particularly strong in rodents, and is a beneficial trait, as they are 
omnivores but unable to vomit. 
 
Conditioned taste avoidance. CTA is considered a special form of classical 
conditioning, where avoidance develops towards the taste or odour of a specific 
foodstuff (conditioned stimulus, CS) and is paired with an unconditioned stimulus 
(US) that is experienced in conjunction with, or relatively soon after, consuming the 
food (Lin et al. 2016, Verendeev and Riley 2012, Welzl et al. 2001). This behavioural 
change prevents the animal from further ingesting a food deemed harmful after its 
consumption, regardless of whether the CS and the US are in reality causally related. 
Unlike taste neophobia, CTA may develop towards familiar foods and even persist for 
weeks or months. 
Classically, the US has been considered to be nausea or gastrointestinal malaise. 
However, CTA has also been repeatedly described following treatments that do not 
induce vomiting in species that are capable of it, and therefore it appears that the 
feeling of nausea or gastrointestinal discomfort is not always required for the effect 
to take place. In fact, CTA can also be instigated when animals are unconscious while 
exposed to CTA-inducing compounds, and likewise by drugs that are rewarding, such 
as amphetamine (Grant 1987, Lin et al. 2012, Lin et al. 2014, Verendeev and Riley 
2012). 
Therefore, it has been suggested that there could be two distinct processes behind 
CTA, conditioned taste aversion and conditioned taste avoidance (Parker 2003). This 
distinction proposes aversion to be displayed by active rejection reactions such as 
gapes, chin rubs and paw treads, and avoidance by reduced appetite and consumption 
in the absence of active rejection. The measurement of taste reactivity, particularly by 
analysis of lick patterns, is also more generally considered essential in the 
characterisation of CTA, as it mirrors palatability and reveals active rejection (Arthurs 
et al. 2012, Lin et al. 2017, Lin et al. 2012). Furthermore, it has been proposed that 
nausea or gastrointestinal discomfort would only be a prerequisite for aversion, while 
avoidance could be related, for instance, to conditioned fear motivated by changes in 
the physiological state in general (Parker 2003). However, there are experimental 
results showing that several compounds not inducing nausea produce aversion as 
analysed by lick patterns (Arthurs et al. 2012, Lin et al. 2017, Lin et al. 2012). 
Therefore, further studies are warranted in order to more precisely define CTA. In 
this thesis research, CTA was considered as a general conditioned taste avoidance 
behaviour, as the assessment of palatability was not possible in the studies performed. 
 
Studies with TCDD have provided support for the involvement of both taste 
neophobia and CTA, as elements of both appear to be involved. The finding that 
chocolate avoidance in rats could be elicited even if chocolate was first presented as 
47 
long as one day after TCDD exposure (Lensu et al. 2011a) strongly argues for 
enhanced neophobia. For CTA to occur, it is considered that the CS and the US should 
be temporally close together. A number of other facts attest to the involvement of 
CTA. Firstly, clear avoidance also emerges, albeit not quite as strikingly, when rats 
have been accustomed to chocolate for a few days or up to a month prior to TCDD 
exposure (Lensu et al. 2011a, J. T. Tuomisto et al. 2000). Secondly, Tuomisto and 
colleagues (2000) showed that rats that had been given chocolate within 12 h of TCDD 
exposure consumed cheese (which at that point was a novel food item for them) on 
day 13 post-exposure equally well compared to the control group. However, these 
same rats still demonstrated chocolate avoidance on day 19 post-exposure. And 
finally, a parallel finding was reported by Lensu and colleagues (2011a) following an 
experiment in which rats were exposed to TCDD and offered an unfamiliar food 
(chocolate or powdered chow), which was subsequently available for one day. Seven 
days after the TCDD exposure coupled with the novel food, the rats preferred a 
completely novel food (powdered chow or chocolate) to the one they had been offered 
as unfamiliar on the day of exposure. 
Two further effects that could be related to novel food avoidance behaviour are 
hypophagia and anxiety. However, TCDD doses that induce novel food avoidance are 
very low, far below those causing wasting syndrome, and do not have an effect on the 
intake of familiar chow (Lensu et al. 2011a). As for anxiety, there are established tests 
in which an increased latency to consume familiar foods in a novel environment 
(hyponeophagia) is indicative of heightened anxiety (Dulawa 2009, Samuels and Hen 
2011). However, a study on TCDD-resistant H/W rats found no indication of 
heightened anxiety after TCDD treatment, even at very high doses, which for most rat 
strains would have been lethal (Sirkka et al. 1992). While these rats are resistant to 
the lethality of TCDD, they are equal to other strains in their sensitivity to most 
biochemical and behavioural responses measured, including novel food avoidance 
behaviour (Lensu et al. 2011b). 
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3 AIMS OF THE STUDY 
The AHR has long been acknowledged as the key mediator in dioxin-induced toxicity. 
In addition, it has important physiological functions. However, knowledge of both of 
these, as well as the underlying mechanisms, is still incomplete. The objective of this 
study was to contribute to the elucidation of some of the many roles of the AHR. The 
overall aim was two-fold: to study the effects of two novel SAHRMs and their 
respective pro-drugs, and to further examine the novel food avoidance behaviour 
previously characterised following TCDD exposure. 
 
The specific aims of this thesis research were to: 
 
1) Characterise selected in vitro effects of the active SAHRMs C1 and C3, 
intended as novel drug compounds for the treatment of AHR-related maladies 
(III); 
 
2) Characterise the acute and subacute in vivo toxicological effects of the 
prodrug-SAHRMs C2 and C4 (II); 
 
3) Find out the extent to which the effects of these novel compounds resemble or 
differ from those of TCDD (I−III); 
 
4) Determine whether novel food avoidance behaviour is AHR-dependent in rats 
(I, unpublished); 
 
5) Further elucidate the mechanisms behind the behaviour and its possible 
connection to CTA, a known behavioural change considered as a special form 
of classical conditioning (I, unpublished). 
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4 MATERIALS AND METHODS 
4.1 Chemicals (I−III, unpublished) 
Selective AHR modulators used in vitro and in vivo (I−III). Novel SAHRMs 
C1, C2, C3 and C4 (Figure 8; Table 3) were studied for their selected toxicological and 
physiological properties in vitro and in vivo. The compounds were kindly provided 
by Dr Lars Pettersson (Immunahr AB, Lund, Sweden). 
C1 and C3 are AHR-active N-hydrogen metabolites of the immunomodulatory 
drug compounds laquinimod and tasquinimod. While C1 and C3 can be used as such 
in vitro, they are unsuitable for in vivo formulations due to their low aqueous 
solubility. Thus, in vivo, the respective acetylated prodrugs C2 and C4 are used, as 
they are readily hydrolysed by xenobiotic metabolism to provide the active 
compounds C1 and C3. 
 
Figure 8. Chemical structures of the novel selective AHR modulators 
In the in vitro experiments, C1 and C3 were studied for their toxicity and ability to 
activate the AHR. Both were dissolved in DMSO (Sigma-Aldrich), and dissolution of 
the high concentration stocks was aided by heating in water baths at +37–65 °C or 
+65–85 °C, respectively, for 30–60 min. For the mammalian cell line experiments, 
the DMSO solutions were further diluted with culture medium before application to 
cells (DMSO concentration applied to cells did not exceed 0.1%). 
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In vivo, C2 and C4 were studied for their toxicity and ability to induce novel food 
avoidance. Stock solutions were prepared by mixing the compounds with PEG-400 
(Ph. Eur. grade, Sigma-Aldrich, St. Louis MO, USA) and heating in a water bath at 
+80–95 °C for 30–60 min, with intermittent vortexing to aid dissolution. Further 
dilutions were prepared from the stocks with PEG-400. 
Table 3. Identification information for the novel selective AHR modulators 
Abbreviation Company 
code 
Chemical name CAS registry 
number 
C1 IMA-06201 N-ethyl-N-phenyl-5-chloro-1,2-dihydro-4-
hydroxy-1-methyl-2-oxo-quinoline-3-
carboxamide 
879410-94-3 
C2 IMA-08401 N-acetyl-N-phenyl-4-acetoxy-5-chloro-1,2-
dihydro-1-methyl-2-oxo-quinoline-3-
carboxamide 
1373260-17-3 
C3 IMA-06504 N-(4-trifluoromethylphenyl)-1,2-dihydro-4-
hydroxy-5-methoxy-1-methyl-2-oxo-
quinoline-3-carboxamide 
1373259-57-4 
C4 IMA-07101 N-acetyl-N-(4-trifluoromethylphenyl)-4-
acetoxy-1,2-dihydro-5-methoxy-1-methyl-2-
oxo-quinoline-3-carboxamide 
1373259-76-7 
 
 
 
Other test compounds used in vitro (II, III). In addition to examining the 
effects of C1 and C3, they were compared with those of TCDD, when relevant. 
Furthermore, the ability of CH-223191 (Sigma-Aldrich, St. Louis MO, USA) to 
antagonise C1 and TCDD was tested. TCDD was purchased from Ufa Institute (Ufa, 
Russia) and was over 98% pure, as assessed by gas chromatography–mass 
spectrometry. Stock solutions of CH-223191 and TCDD were prepared by dissolving 
them in DMSO (Sigma-Aldrich). The stocks were further diluted with cell culture 
medium before application to cells (maximum DMSO concentration applied to cells 
was 0.1%). 
Chemicals used as positive controls included Triton X, BaP, sodium azide, 2-
aminoanthracene, and mitomycin c (all from Sigma-Aldrich). Apart from Triton X, 
they were dissolved in either H2O or DMSO (final DMSO concentration on H4IIE cells 
was 0.1%, and 1.85% in the Ames test on Salmonella Typhimurium cells). 
 
Other test compounds used in vivo (I, unpublished). For the novel food 
avoidance behaviour experiments, AHR agonists FICZ, BNF and BaP were used in 
addition to C2. Furthermore, a constitutive androstane receptor (CAR) agonist, TPD, 
was used to study whether phenobarbital-induced xenobiotic metabolising enzyme 
activation, following the induction of CAR instead of AHR, would lead to similar novel 
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food avoidance behaviour. AHR antagonists CH-223191 and GNF351 were used to 
test whether the avoidance response could be alleviated. 
FICZ was purchased from Enzo Life Sciences (Farmingdale NY, USA) and BNF, 
BaP and CH-223191 from Sigma-Aldrich. GNF351 Calbiochem® was from Merck 
(Darmstadt, Germany). TPD was courtesy of Dr Vladimir O. Pustylnyak (Institute of 
Molecular Biology and Biophysics SB RAMS, Novosibirsk, Russia). 
FICZ, TPD, CH-223191 and GNF351 were first dissolved in DMSO and then 
diluted with sunflower oil [Keiju, Bunge Finland Oy, Raisio, Finland; final DMSO 
concentrations 2.5% or 6% (v/v)]. BNF and BaP were mixed with either DMSO and 
sunflower oil or just sunflower oil and heated in a water bath at +95 °C for 1 h, 
resulting in suspensions [final DMSO concentrations 2.5% (v/v)]. 
4.2 H4IIE cell line (II, III) 
The H4IIE rat hepatoma cell line (H-4-II-E ATCC® CRL1548™) was acquired from 
ATCC (Manassas VA, USA). The cell line was selected for its highly inducible 
expression of CYP xenobiotic metabolising enzymes (Fujimura et al. 2012). In 
addition, it has been shown to be exceptionally responsive to CYP1A1 induction by 
dioxins (Bradlaw and Casterline Jr. 1979, Sawyer and Safe 1982). 
The cells were cultured in monolayers at 37 °C and 5% CO2 in low glucose Eagle’s 
Minimum Essential Medium (EMEM; ATCC) or low glucose Dulbecco’s Modified 
Eagle Medium (Gibco® DMEM, Thermo Fisher Scientific, Paisley, Scotland, UK), 
depending on the following experiment. Both media were supplemented with 10% 
FBS (Sigma-Aldrich) for cell culturing. Cell passages from 2 to 6 were used for the 
experiments. The MycoAlert™ Mycoplasma Detection Kit (Lonza Group Ltd, Basel, 
Switzerland) was periodically used to ensure that the cells used in the experiments 
were free of infection. 
4.3 Animals and their husbandry (I, II, unpublished) 
For I, II and an unpublished experiment, male Sprague Dawley (SD) rats were 
purchased from Harlan Netherlands. For the unpublished experiment, the rats were 
vagotomised. The operations were performed at Harlan, allowing for recovery before 
shipment. In addition, for another unpublished experiment, AHR-knock-out SD rats 
(AHRKO) were bred in the laboratory animal centre of the University of Helsinki. For 
this purpose, a pair of homozygous AHRKO rats (SD-Ahrtm1sage) was acquired from 
Horizon Discovery (Waterbeach, Cambridge, UK). This rat strain, originating from 
wild-type (WT) SD rats, harbours a deletion mutation of 760 base pairs in exon 2, 
which contains the DNA-binding bHLH motif of the AHR gene. 
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In order to establish a specific pathogen-free colony, the KO male was paired with 
a pathogen-free, superovulated WT SD female (from Harlan). Subsequently, the 
embryos were transferred to a pseudopregnant recipient female. The resulting 
heterozygote offspring consisting of three females were paired with a WT male 
(Harlan). Subsequent heterozygote progeny were further paired with each other 
(avoiding littermate pairings) to gain homozygote AHRKO and littermate WT rats for 
use in experiments. Genotyping of the rats was performed by PCR (details in chapter 
4.17) using gDNA extracted from ear punches. 
All rats were acclimatised to the study conditions and handling for a minimum of 
one week before commencing the experiments. Throughout the studies, they were 
housed in individually ventilated plastic cages (Sealsafe IVC Blue Line or Green Line 
IVC Sealsafe PLUS Rat, Techniplast, West Chester PA, USA), and maintained on a 12-
h light/dark cycle (06:00−18:00). The cage floor was covered with aspen wood 
bedding (Tapvei, Estonia), and each cage was enriched with a transparent red plastic 
hiding tube, nesting material and chew blocks (both aspen wood, Tapvei, Estonia). 
Commercial pelleted rat chow [RM1 (E) SQC Expanded, SDS Diets, Witham, Essex, 
England; or equivalent Teklad Global 16% Protein Rodent Diet, Teklad Diets, 
Madison WI, USA] and filtered, UV-irradiated tap water were available ad libitum. 
The animal room was air-conditioned: the temperature was kept at 22 ± 1 °C and the 
relative humidity at 38–75% (typically 50%). 
 
Ethical issues (I, II, unpublished). In vivo studies were authorized by the 
National Animal Experiment Board in Finland (Eläinkoelautakunta, ELLA; project 
licence code ESAVI/6882/04.10.03/2012). All procedures were conducted in a 
humane manner and in accordance with Directive 2010/63/EU of the European 
Parliament and of the Council. 
4.4 Cytotoxicity assay (III) 
The cytotoxicity of C1, C3 and TCDD was assessed in H4IIE cells using the 
Cytotoxicity Detection Kit (LDH; Roche Diagnostics GmbH, Mannheim, Germany), 
which measures lactate dehydrogenase (LDH) leakage. A total of 25,000 cells were 
seeded per well in 96-well plates (Greiner Bio-One GmbH, Kremsmünster, Austria) 
~18 h prior to exposures. The outer and corner wells were left empty of cells and only 
filled with PBS to avoid the edge effect. As recommended in the manual, the medium 
(EMEM) was supplemented with 1% FBS for the assay to prevent LDH in serum from 
increasing the background absorbance. The concentrations of the test compounds 
used were 10, 100 and 1000 nM for C1 and C3, and 10 and 100 nM for TCDD. Cells 
were exposed for 6 h and 24 h. The vehicle was used as a negative control (0.1% 
DMSO) and Triton X-100 (1%) as a positive control. Background controls (assay 
medium without cells, with and without vehicle) were also included. All exposures 
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were performed in triplicate in two independent experiments. Culture supernatants 
were collected, and the assay was performed according to the manufacturer’s 
instructions. Absorbances were measured with an ELISA reader at 492 and 620 nm 
and corrected for the measured background absorption (Multiskan Ascent, Thermo 
Fisher Scientific). Cytotoxicity was calculated as a percentage using the following 
equation: [(exp. value - negative control) / (positive control - negative control) * 100]. 
The negative control was thus at 0% cytotoxicity and the positive control at 100%, and 
the cytotoxicity of the test compounds expressed relative to these. 
4.5 MTT reduction assay (III) 
The effect of C1, C3 and TCDD on cell viability/metabolic activity in vitro was assessed 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
reduction assay in H4IIE cells. The colorimetric MTT assay is based on the 
information that viable cells with active metabolism convert the yellow tetrazolium 
dye MTT into a purple formazan product, which can be measured. When cells die, 
they can no longer perform this conversion. The molecular pathways involved in 
disturbances in MTT reduction into formazan are not well understood, but in 
controlled study conditions, the amount of formazan product formed by NAD(P)H-
dependent cellular oxidoreductase enzymes is in proportion to the number of 
metabolically active, viable cells (Riss et al. 2013 (Updated 2016)). Therefore, and as 
the data from the test compounds were compared with the vehicle controls (100% 
viability and metabolic activity), the result was interpreted to reflect the reduction in 
metabolic activity. 
Altogether, 24,000 H4IIE cells were seeded per well in 96-well plates (Greiner 
Bio-One GmbH) 24 h prior to exposures. The outer and corner wells were only filled 
with PBS to avoid the edge effect. The medium used in the assay was low-glucose, 
phenol red-free DMEM (Gibco® DMEM, Thermo Fisher Scientific, Paisley, Scotland, 
UK) supplemented with 4 mM L-glutamine (Thermo Fisher Scientific), 
corresponding to the standard DMEM used for culturing the cells prior to the 
experiment. The medium used in the experiment was further supplemented with 1% 
FBS (Sigma-Aldrich). 
The cells were exposed to the vehicle, C1, C3 or TCDD for 6 h or 24 h at 5−6 
concentrations (1, 10, 50, 100, 500 and 1000 nM of C1 and C3 on cells; 1, 5, 10, 50 
and 100 nM of TCDD). All exposures were performed in triplicate in two independent 
experiments. After exposures, the cells were washed once with PBS and treated with 
MTT for 5 h (Sigma-Aldrich; final concentration 1 mg/ml). The medium was then 
gently removed, and formazan crystals were dissolved in 200 μl of DMSO containing 
0.1 M glycerine and 0.1 M NaCl. After incubation at room temperature for 10 mins, 
the absorbances were measured with an ELISA reader at 595 nm (Multiskan Ascent, 
 54 
Thermo Fisher Scientific). The results were calculated as a percentage over the 
controls. 
4.6 CYP1A1 induction assay (II, III) 
The CYP1A1 enzyme induction potential of C1, C3 and TCDD was tested in vitro in 
the metabolically active H4IIE cell line using a luminescent assay. CYP1A1 induction 
was utilised to represent AHR activation in general, as it is a well-established, fairly 
rapid and highly sensitive index of AHR activation (Abraham et al. 1988). The aim 
was to compare the potency and efficacy of the novel compounds with those of TCDD. 
In addition, the ability of the specific AHR antagonist CH-223191 to block the effect 
of C1 and TCDD was tested. 
Several independent experiments were performed in 96-well plates (Greiner Bio-
One GmbH, Kremsmünster, Austria). Cells were seeded at 10,000 cells/well and 
allowed to equilibrate for about 40 h prior to exposures. The outer and corner wells 
were left without cells and filled with PBS in order to avoid the edge effect. The cells 
were then exposed for 24 or 48 h to varying concentrations of C1, C3 and TCDD (1, 
10, 100, 500 pM and 1, 5, 10, 50 and 100 nM, and furthermore 1000 nM of C1 and 
C3). In addition, a combination of C1 or TCDD and CH-223191 (1 nM and 100 nM, 
respectively) was used. The controls were exposed to the vehicle (0.1% of DMSO in 
culture medium). For 48-h exposures, culture medium with the test compounds was 
replaced with fresh medium at 24 h and the exposures repeated. All exposures were 
performed in triplicate. 
CYP1A1 activity was detected with the P450-Glo™ CYP1A1 Assay (Promega, 
Madison WI, USA) according to the manufacturer’s instructions. Subsequently, the 
CellTiter-Glo® Luminescent Cell Viability Assay (Promega) was used to confirm that 
there were no significant differences between the numbers of viable cells in the wells 
at the time of detection. The assay is based on the quantitation of ATP. 
4.7 Ames test (III) 
The genotoxicity of C1 and C3 was first examined by the standard plate incorporation 
mutagenicity test, which was performed according to the principle of Maron and 
Ames (1983). Briefly, TA98 and TA100 Salmonella Typhimurium strains were used, 
and the test was performed both with and without metabolic activation, using 10% S9 
SD rat liver mix (Trinova Biochem GmbH, Giessen, Germany). Water and DMSO 
(1.85% on plates) were used as negative controls for both strains. As positive controls 
for TA100 and TA98, respectively, sodium azide (0.04 mg/ml) or 2-aminoanthracene 
(0.2 mg/ml) was used. In addition, BaP (0.1 mg/ml) was used as a positive control for 
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both strains. The volume of both control and test compounds was 50 μl per plate. Two 
independent tests were performed. Within each test, triplicate or quadruplicate plates 
were prepared for each compound and dose, and for all controls. In the first test, C1 
and C3 were assayed at concentrations of 0.375, 0.75, 1.5 and 3 mg/ml, resulting in 
plate concentrations of 17.5–170 μM. In the second test, plate concentrations of 1 nM, 
100 nM, 10 μM and 1 mM were used. All plates were incubated at 37 °C for 72 h before 
calculation of colonies. 
4.8 In vitro micronucleus test (III) 
The Ames test is able to detect only mutagens. Therefore, to further assess any 
genotoxic properties of C1 and C3, also an in vitro micronucleus test, which detects 
chromosomal aberrations, was performed on the H4IIE cell line. TCDD was included 
here in addition to C1 and C3. 
A total of 40 000 cells were seeded in 12-well plates (Greiner Bio-One GmbH) 24 
h prior to exposures. The medium employed was low-glucose, phenol red free DMEM 
(Gibco® DMEM, Thermo Fisher Scientific) supplemented with 4 mM L-glutamine 
(Thermo Fisher Scientific) and 10% FBS, corresponding to the standard DMEM used 
for culturing the cells prior to the experiment. S9 mix was not employed, as the cell 
line has retained a considerably high metabolic activity (Fujimura et al. 2012).  
Mitomycin c was used as a positive control, and vehicle as a negative control. The 
final concentrations on cells were: 100, 500, and 1000 nM of C1 and C3; 10, 50, and 
100 nM of TCDD; and 500 nM of mitomycin c. All exposures were performed in 
triplicate in a single experiment. The exposure time was 24 h, after which the cells 
were treated with cytochalasin B (4 μg/ml; Cayman Chemical, Ann Arbor, MI USA) 
for 1.5–2 normal cell cycle lengths, ~28 h. Next, the cells were washed twice with PBS 
and fixed with 4% paraformaldehyde for 10–15 min (in PBS, pH 6.9; Sigma) before 
washing again with PBS. For detection, the cells were stained with 10% Giemsa 
solution (Merck KGaA, Darmstadt, Germany) and the micronucleus frequencies were 
analysed at 1000 binucleated cells per well. 
4.9 In vivo experimental design 
Within all in vivo experiments, rats were randomly allocated into groups, which were 
matched for body weight (BW) and, when necessary, genotype (unpublished 
experiments with AHRKO rats). In all experiments, rats were weighed immediately 
before exposures and dosed according to BW. In all novel food avoidance behaviour 
studies (I, unpublished), rats were housed singly during the experiments to allow the 
measurement of novel food consumption. In II, rats were housed in groups 
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throughout the experiments. At the end of the studies, carbon dioxide was used for 
euthanasia and samples were collected. 
4.9.1 Acute and subacute toxicity of the novel SAHRMs (II) 
Acute toxicity. The study was carried out on ~9-week-old male SD rats as a pilot 
experiment. The aim was to ensure that the pro-drugs C2 and C4 would not cause 
marked acute toxicity before their repeated administration to larger groups of 
animals. The study principle was loosely based on the OECD test guideline for acute 
oral toxicity [Up-and-Down-Procedure (OECD 2008)] to reduce the number of 
animals required. 
Single doses at three different dose levels were tested for both compounds, 8.75–
92.5 mg/ml for C2 and 8.75–75 mg/ml for C4. The high doses were limited by the 
maximum achievable solubility of the compounds. The volume administered was 5 
ml/kg, and all groups were dosed intragastrically (ig) by oral gavage. Post-exposure, 
the rats were monitored for 7−13 days before necropsy. 
As the number of rats in each group was low in this experiment (n = 1–3, except 
for controls where n = 6), the data from it were considered preliminary, and statistical 
evaluation was only performed among the controls and the highest doses of C2 and 
C4 (n = 3). 
 
Subacute toxicity. Likewise, ~9-week-old male SD rats (n = 5−6 in each group) 
were employed to explore the toxicological properties of C2 and C4 after repeated 
administrations. The substances were administered once a day on five consecutive 
days at the highest concentrations attainable, which had proven to not be acutely toxic 
in the pilot experiment. These were 75 and 100 mg/kg/day for C4 and C2, respectively 
(5 ml/kg, ig). After the last exposure, the rats were further monitored and weighed 
for five days before necropsy for any delayed clinical signs. At necropsy, body and 
selected organ weights (thymus, liver, kidneys, testes and spleen) were determined, 
and serum and tissue samples (liver, duodenum, kidney, testis and lung) were frozen 
in liquid nitrogen for further processing (chapters 4.10−4.14). In addition, liver, 
spleen, kidney, lung and testis samples were collected for histopathology (chapter 
4.13). 
4.9.2 Novel food avoidance behaviour studies (I, unpublished) 
Novel food avoidance behaviour was studied in several experiments described below. 
All exposures were performed in the forenoon, between 10:30–12:00. The dosing 
route in all experiments was either ig or ip, and the volume dosed was 4 or 5 ml/kg. 
These were kept constant across groups within experiments, and also between them 
when possible. Apart from a 3-h fast before ig dosing, normal chow was available 
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concurrently with the novel food throughout the studies. Tissue samples were 
collected after euthanasia from most studies to determine whether the AHR had been 
activated (analysed by RT-qPCR as Cyp1a1 induction). 
As in many of the earlier studies with TCDD, the novel food item used in all of the 
experiments was milk chocolate, which rats typically find highly palatable. In 
addition, chocolate keeps well at room temperature, and its consumption is easy to 
measure: the level of quantification is low (down to 10 mg, depending on the 
sensitivity of the scales used), and discriminating even between a single bite (tasting) 
and no bite is easy. 
 
Ability of AHR agonists to induce novel food avoidance (I). Previously, novel 
food avoidance behaviour had only been studied after TCDD exposure (Lensu et al. 
2011a, Lensu et al. 2011b, J. T. Tuomisto et al. 2000). In I, the aim was to determine 
whether the effect is specifically characteristic of TCDD, or whether it can also be 
induced by other AHR activators. To this end, male SD rats (n = 6/group) were 
exposed to single ig doses of the established AHR agonists FICZ (0.1 mg/kg), BNF 
(60 mg/kg) and BaP (150 mg/kg). The doses used were set based on previous 
literature demonstrating that they activate the AHR in vivo (Hodek et al. 2013, Mukai 
and Tischkau 2007, Wincent et al. 2012). Furthermore, in a separate experiment, 
single ig doses of the SAHRM C2 were tested, similarly in SD male rats, at three dose 
levels (4, 20 and 100 mg/kg; n = 6/group). In both experiments, chocolate was placed 
in each cage directly post-exposure, and its consumption measured for a minimum of 
24 h, or as long as the avoidance response persisted. 
 
Dependence of the response on the AHR (I, unpublished). Findings in a 
previous study with TCDD in AHRKO mice had already implied the specific 
involvement of the AHR in the avoidance response (Lensu et al. 2011b). Here, the aim 
was to confirm in SD rats whether, in addition to a correlation, there is indeed 
causality between AHR activation and the novel food avoidance behaviour. To this 
end, in I, alleviation of AHR-activator-induced novel food avoidance was attempted 
with two different AHR antagonists, CH-223191 and GNF351. They were 
administered separately ig as single doses (13 mg/kg of CH-223191 and 5 mg/kg of 
GNF351), in addition to single doses of FICZ (0.1 mg/kg, ig; n = 6/group). 
Furthermore, single doses of CH-223191 and C2 were tested: 10 mg/kg, ip of the 
antagonist together with 20 mg/kg, ig of C2, and 4 mg/kg, ig of C2 together with 15 
mg/kg, ig of antagonist (n = 6/group). 
Moreover, an AHRKO rat line was acquired (details in 4.3), which allowed directly 
exploring the involvement of the AHR in the response. In an unpublished experiment, 
it was tested whether BNF (60 mg/kg, 4 ml/kg, ig) would induce novel food avoidance 
behaviour in male AHRKO rats. Two experiments both consisted of four groups: 
AHRKO and littermate WT BNF groups, and control groups of both genotypes. The 
first experiment (n = 3/group) was conducted as before, and novel chocolate was 
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placed in the cages directly after exposures. However, both genotypes of this rat line 
behaved somewhat differently compared to the Harlan SD rat line used in previous 
experiments, with controls exhibiting a considerably slower onset of chocolate 
consumption, possibly reflecting enhanced neophobic behaviour in this strain. 
Therefore, in the second experiment (n = 6–7/group), the study design differed 
somewhat from the previous one. Chocolate was employed as the novel food item, as 
before, but was now placed in each cage for ~24 h prior exposure to BNF. The 
rationale was to ensure that each rat was familiar with chocolate by exposure, and 
that it did not exhibit neophobic behaviour. This also allowed approaching the 
question of the two possible underlying food avoidance phenomena, neophobia and 
CTA, because for CTA to develop, association of a taste (or odour) with the stimulus 
is essential, and in classical CTA designs it is typically presented prior to the stimulus. 
Post-exposure, chocolate consumption was measured, and the rest of the experiments 
were performed as before. 
Furthermore, in the previous studies with TCDD, there was a conspicuous 
correspondence between ED50 values for the induction of hepatic CYP1A1 and the 
avoidance behaviour among all three tested, differentially TCDD-sensitive rat strains 
(Lensu et al. 2011b). Since AHR signalling is by far the predominant positive regulator 
of Cyp1a1 gene expression (Q. Ma 2001), the finding suggested a possibility of a causal 
relationship between AHR activation in the liver and the behavioural change (Lensu 
et al. 2011b). In theory, AHR-induced induction of xenobiotic metabolising enzymes 
might not only be an index of AHR activation, but also functionally related to the 
mode of action of this behavioural change, e.g. by generating a critical mediator 
metabolite. However, the avoidance response could also be dependent on the 
enhancement of metabolic enzyme activation more generally, and not specifically in 
relation to activation of the AHR. 
The latter question was approached in I by testing the effect of TPD, a 
phenobarbital-type inducer of CAR, a nuclear receptor likewise heavily involved in 
xenobiotic metabolism, but largely through CYP2B enzymes (Pustylnyak et al. 2009). 
The experiment was conducted identically to the experiment with FICZ, BNF and 
BaP, but 10 mg/kg of TPD was administered (n = 12 in TPD group, 6 in controls). 
 
Persistence of the effect in the absence of novel food (I). In I, the persistence 
of novel food avoidance was also explored when access to the novel food was 
restricted. In this experiment, the rats were first exposed to either FICZ (0.1 mg/kg) 
or BNF (60 mg/kg), and then allowed access to novel chocolate on two occasions: first 
for a mere 6 h directly post-exposure, and again after a two-week interval, when it 
was left in the cages. Each group consisted of six rats. 
 
Effect of vagotomy on the avoidance response (unpublished). The 
acquisition of CTA requires the activation of several brain regions. It was 
hypothesised that the novel food avoidance behaviour seen with AHR agonists would 
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similarly necessitate the activation of neuronal pathways. In I, the results had 
suggested that the stomach or the upper gastrointestinal tract might be a possible 
initial key target tissue for the avoidance behaviour. Thus, as the sensory input from 
the digestive tract, especially from its oral end, is mainly transmitted to the brain via 
the vagus nerve, it was examined whether blocking these messages by vagotomy 
would have an effect on the avoidance behaviour. 
To this end, a single dose of BNF (60 mg/kg) was administered to vagotomised 
male SD rats (n =6/group) and chocolate offered as a novel food item directly post-
exposure. 
4.10 Clinical chemistry analysis (II) 
Following the subacute toxicity study, clinical chemistry analyses from serum were 
carried out at the Central Laboratory of the Department of Equine and Small Animal 
Medicine, University of Helsinki. Enzymatic methods were used for the 
determination of serum FFA (a.k.a. long-chain fatty acids [LCFA] or non-esterified 
fatty acids [NEFA]) (NEFA-C, Waco Chemicals GmbH, Neuss, Germany) and D-3-
hydroxybutyrate (3-HB; RANBUT, Randox Laboratories Ltd. Crumlin, UK). The 
analyses were performed with an automatic chemistry analyser (KONE Pro Selective 
Chemistry Analyser, Thermo Fisher Scientific). The rest of the serum analytes 
[alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), total 
bilirubin, creatinine, glucose, triglyceride, cholesterol and urea] were analysed using 
the reagents and adaptations recommended by the manufacturer of the automatic 
chemistry analyser (Konelab 30i, Thermo Fisher Scientific). 
4.11 Thyroxine level measurement (II) 
Thyroxine (T4) levels were measured in serum samples collected at the termination 
of the subacute toxicity study. For this, the Rat Thyroxine T4 ELISA Kit (Cusabio 
Biotech Co. Ltd, Wuhan, China) was used according to the manufacturer’s 
instructions.  
4.12 Retinoid concentration measurement (II) 
Retinoid concentrations from serum, liver and kidney samples from the subacute 
toxicity study were measured at Instituto de Bioingeniería, Universidad Miguel 
Hernández de Elche (Alicante, Spain). Briefly, the different retinoid forms, extracted 
from tissue homogenates or serum, were separated by HPLC and detected by UV at 
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340 nm for retinoic acid derivatives (Schmidt, et al. 2003a), and at 325 nm for retinol 
and retinyl palmitate (van der Ven, et al. 2009), i.e. the polar and apolar retinoid 
forms, respectively. 
4.13 Histopathological analysis (II) 
Following the subacute toxicity study, liver, spleen, kidney, lung and testis samples 
were prepared and analysed at the Finnish Centre for Laboratory Animal Pathology 
(FCLAP), University of Helsinki. Briefly, the samples were fixed in 4% buffered 
formalin, embedded in paraffin and sectioned at 4 μm thickness. Slides were stained 
with haematoxylin-eosin for histopathological analysis. 
4.14 RNA isolation from tissue samples (I, II, unpublished) 
RNA was extracted from tissue samples for reverse transcription real-time 
quantitative PCR (RT-qPCR). Briefly, total RNA was isolated from bead-milled 
(TissueLyser LT, Qiagen, Hilden, Germany) tissue samples using the Sigma 
GenElute™ Mammalian Total RNA Miniprep Kit according to the manufacturer’s 
protocol (Sigma-Aldrich). RNA was then treated with Ambion® TURBO DNA-free™ 
DNase treatment and removal reagent (Life Technologies, Carlsbad CA, USA). The 
concentration of total RNA was measured with a Nanodrop UV Spectrophotometer 
(Thermo Fisher Scientific) and RNA purity verified by 260/280 and 260/230 nm 
ratios. 
4.15 RT-qPCR analysis of AHR-battery genes (I, II, 
unpublished) 
RT-qPCR was performed to determine the expression of selected AHR-battery 
xenobiotic metabolising enzyme genes and Cyp2b1 mRNA levels. The AHR-battery 
genes are a set of genes mainly encoding xenobiotic metabolising enzymes that 
include Cyp1a1, Cyp1a2, Nqo1 and Ugt1a6 (Nebert et al. 2000). Of these, induction 
of the Cyp1a1 gene, in particular, is employed as a biomarker of AHR activation, as 
its induction is fairly rapid and it is highly sensitive (Abraham et al. 1988). 
Total RNA was reverse transcribed to complementary DNA (cDNA) at 50 °C for 
1 h using M-MLV RT RNase H-Point Mutant (Promega, Fitchburg WI, USA). For each 
reaction (25 μl), 50 or 100 U of the enzyme and 400 or 800 ng of RNA (respectively) 
was used. Quantitative real-time PCR (qPCR) was performed using HOT FIREPol® 
EvaGreen® qPCR Mix Plus (no ROX; Solis Biodyne, Tartu, Estonia) on Rotor-Gene 
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3000 or Rotor-Gene Q instruments (Qiagen, Hilden, Germany). This was carried out 
by absolute quantification, using the diluted total cDNA amount for normalization 
(20 ng/reaction, assumed based on the original amount of RNA in RT reactions; 
information on target gene specific primers in II, Supplementary Table 1) (Bustin 
2002, Tichopad et al. 2009). Each cDNA sample was run in a duplicate reaction to 
obtain technical replicates. No-template controls were included in each run to control 
for reagent contamination. Primer specificity was confirmed by melt curve analysis at 
the end of each run. If the RT-qPCR result was below the detection limit, a 
conservative approach was taken and the sample was given the value of the limit. 
The primers (Supplementary Table 1 in II) were designed based on the published 
genome sequences of the target genes using the Primer3web 4.0.0 web interface 
(Koressaar and Remm 2007, Untergasser et al. 2012). Standard curves were 
constructed for each primer pair by preparing a 10-fold dilution series starting from 
known concentrations of isolated and purified target gene PCR products amplified 
from cDNA samples, using the same primers as for RT-qPCR. 
4.16 Molecular docking analysis (III) 
In silico molecular modelling analyses were performed at the Department of Earth 
and Environmental Sciences, University of Milano-Bicocca, Italy. Briefly, a three-
dimensional structure of the rat AHR LBD previously obtained (Motto et al. 2011) by 
homology modelling using MODELLER (Webb and Sali 2016) was employed. The 
molecular structures of C1 and C3 were subjected to conformational analysis 
performed by ab initio Quantum Mechanical (QM) calculations, using Jaguar 
(Schrödinger Release 2016-4: Jaguar, LLC, NY USA). Molecular Docking calculations 
were performed using Glide extra precision (XP; Schrödinger Release 2016-4: Glide). 
To include part of the domain flexibility involved in ligand binding, different 
modelled conformations of the AHR LBD were used for docking (ensemble-docking 
technique). One binding geometry (pose) was obtained for each ligand in each 
modelled receptor conformation, and the most favourable pose was selected by 
calculating the binding free energies with the Prime MM-GBSA approach 
(Schrödinger Release 2016-4: Prime). 
4.17 Genotyping of the AHR knockout rat line (unpublished) 
As both AHRKO and WT rats were required for the experiments, heterozygote rats 
were used for breeding the AHRKO rat line and all pups genotyped. For genotyping, 
genomic DNA (gDNA) was extracted from ear punches using hot sodium hydroxide 
and tris (HotSHOT) (Truett et al. 2000). The target gene was then amplified by 
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conventional PCR and DNA bands imaged under UV light after running the samples 
on ethidium bromide-stained 1–1.5% (w/v) agarose gels.  
Briefly, ear punch samples were lysed in 25 mM NaOH and 0.2 mM disodium 
EDTA solution (pH ~12) by heating for 25 min at +95 °C. The samples were then 
cooled on ice and the lysates neutralised with 40 mM Tris-HCl (pH ~5), vortexed and 
centrifuged lightly. Four microlitres of supernatant was used for each PCR reaction 
(total volume 20 μl). The PCR reactions were performed using either JumpStart Taq 
DNA Polymerase (Sigma-Aldrich) or Universe High-Fidelity Hot Start DNA 
Polymerase (Bimake.com, Houston TX, USA) with target-gene-specific primers 
(Table 4). The reactions were amplified in Axygen® MaxyGene™ II thermal cyclers 
(further information on the PCR reactions provided in Table 4). Subsequently, 4 μl of 
loading dye was added to each sample, and reactions were loaded on 20 x 20 cm gels 
and electrophoresed at 110 V for 1 h in 1 x TAE buffer. Finally, the gels were imaged 
under UV light. 
Table 4. Further information on the PCR reactions in genotyping the AHRKO rat line. 
Enzyme JumpStart Taq DNA 
Polymerase 
Universe High-Fidelity Hot 
Start DNA Polymerase 
Forward primer cgggtgtgtctgttaatggc (Same) 
Reverse primer tcctctcttgtccactgagc (Same) 
Supplements in PCR reactions 
(including H2O, buffer, dNTP, 
primers, enzyme, and DNA) 
MgCl2, DMSO Bovine serum albumin 
Amplification 95 °C for 1 min; 35 cycles: 
95 °C for 30 s, 59 °C for 30 s, 
and 72 °C for 1 min 45 s; 
followed by 72 °C for 5 min. 
95 °C for 3 min; 35 cycles: 
95 °C for 15 s, 57 °C for 20 s, 
and 72 °C for 40 s; followed by 
72 °C for 5 min. 
 
4.18 Statistical analysis (I−III, unpublished) 
SPSS Statistics software was applied for statistical analysis, and the level of 
significance was set at p < 0.05, unless otherwise specified (IBM Corp. Released 2013. 
IBM SPSS Statistics for Windows, Version 22.0 or 24.0 Armonk NY, USA). 
Most statistical analyses were carried out by one-way analysis of variance 
(ANOVA) followed by pairwise comparisons with Dunnett’s test, Student-Newman-
Keuls or Duncan’s new multiple range post-hoc tests. In case the data were not 
normally distributed and variances were non-homogenous (as assessed by Levene’s 
test), values were log-transformed in order to restore homogeneity, and then re-
analysed by one-way ANOVA. In addition, results were verified by re-analysing the 
data with Kruskal-Wallis non-parametric ANOVA, followed by the Dunn-Bonferroni 
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post-hoc multiple comparison test. If data were normally distributed but variances 
were non-homogenous, post-hoc testing was performed by Games-Howell. When 
only two groups were compared with each other, the Student’s t-test for independent 
samples was used. If t-test requirements were severely violated, the results were 
verified with the Mann-Whitney U-test. 
Mixed between/within subject ANOVAs were used to analyse the data for repeated 
measurements over time in I and II. For this purpose, the normal distribution of the 
data was verified using Shapiro-Wilk’s test, equality of error variances and covariance 
matrices were assessed using Levene’s and Box’s tests, respectively, and the 
homogeneity of the variances of the differences between all combinations of levels of 
the within-subjects factor (sphericity) was assessed with Mauchly’s test. For one-way 
ANOVAs, significant main effects were further analysed by pairwise comparisons 
using Dunn’s (1964) procedure with a Bonferroni correction for multiple 
comparisons, and the Kruskal-Wallis H-test followed by multiple comparisons. For 
two-way ANOVAs, simple main effects were analysed by univariate ANOVA and the 
Tukey HSD post-hoc test. In Box’s test, only p-values of < 0.001 were considered 
significant. 
In II, retinoid concentrations were analysed using R software version 3.2.3 (R 
Development Core Team, R Foundation for Statistical Computing, Vienna, Austria). 
Pairwise multiple comparisons between exposed and control means were performed 
using ANOVA and linear contrast tests. In addition, Box plots were used for 
verification of a normal distribution. 
Furthermore, in II, the 24-h luminescence data from the in vitro CYP1A1 enzyme 
activity assay were analysed by two-way ANOVA. The significance level for the 
interaction term was set at p < 0.001 in the case of non-homogenous variances 
(assessed by Levene’s test) and a slight deviation from a normal distribution in some 
datasets (assessed by Shapiro-Wilk’s test). Simple main effects were assessed by 
multiple pairwise comparisons with Bonferroni’s adjustment. In III, the 48-h dose–
response data from the CYP1A1 activity assay were analysed in GraphPad Prism using 
nonlinear regression with four-parameter logistics (GraphPad Software, Inc., Prism 
7 for Windows, Version 7.03, La Jolla, CA USA). The data from the micronucleus test 
in III were statistically assessed by the Cochran-Armitage test for trend in 
proportions. 
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5 RESULTS 
5.1 Characterisation of novel SAHRM effects 
5.1.1 Toxicity in vitro (III) 
LDH leakage assay. C1, C3 and TCDD were not cytotoxic in the LDH leakage assay. 
There was no dose response, and the maximum cytotoxicity caused by all three test 
compounds was only 5% at the concentrations tested, which was not statistically 
significant (Supplementary Figure 1 in III). In pairwise comparisons following one-
way ANOVA (p < 0.001), the only group that differed from the others in a statistically 
significant manner (p < 0.001) was the positive control, 1% Triton X. 
 
MTT reduction assay. A dose-dependent decrease in MTT reduction was observed 
for all three compounds, but at differing time points and concentrations (Figure 3 in 
III). At 6 h, multiple comparisons showed that for C1, the three highest concentrations 
(100, 500 and 1000 nM) differed statistically significantly from the vehicle controls, 
while C3 only had an effect at the highest concentration of 1000 nM. The MTT 
reduction capacities after 1000 nM exposures of C1 and C3 were down to 82% and 
84% of controls, respectively. At 6 h, TCDD did not show a reducing effect at any of 
the concentrations tested (1–100 nM). 
At 24 h, a significant decrease in MTT reduction was likewise only seen with C3 at 
the highest concentration. The results for C1 and TCDD were reversed compared with 
the 6-h time point. At 24 h, C1 did not induce a statistically significant effect at any 
concentration. With TCDD at 24 h, there was a statistically significant difference 
compared with the controls at the highest concentration tested, 100 nM, and the effect 
was more intense (down to 76%) than that of C1 and C3 at 100 nM or even 500 nM at 
either time point. For C1 and C3, the MTT reduction capacities at the highest 
concentrations were down to 82% and 77% of controls, respectively. 
Interestingly, and unlike with TCDD, the effects of C1 and C3 did not intensify 
dramatically between 6 h and 24 h. Furthermore, between the 6- and 24-h time 
points, at concentrations of up to 100 nM, the MTT reduction capacity of cells treated 
with C1 and C3 appeared to have even slightly recovered, showing systematically 
slightly less of a reduction at 24 h than at 6 h. 
 
Ames test. In the Ames test, C1 and C3 did not appear mutagenic in the dose range 
tested (1 nM–1 mM) in either of the strains used, TA100 and TA98. The number of 
revertants obtained with all tested concentrations of C1 and C3 was ≤ ~1-fold of the 
negative controls. The negative controls performed consistently, and the positive 
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controls also performed adequately overall, and all of them gave statistically 
significant positive results compared with the negative controls. However, in some 
cases, the indirect mutagen BaP gave rather low numbers of revertants with metabolic 
activation, indicating that the microsomal S9 mix did not work as efficiently as 
desired. 
Some cytotoxicity was observed in the TA98 strain. The systematic dose responses 
were observed with metabolic activation by C1 at or above ~20 μM, and by C3 at or 
above ~70 μM, and without metabolic activation at the highest concentration of 1 mM 
by both C1 and C3. Furthermore, the plate concentration of 1 mM can be considered 
the maximum achievable, as both C1 and C3 already precipitated at this concentration 
when added to the master mix prior to plating. 
 
Micronucleus test. As a minimum, a dose-dependent tendency towards increased 
frequency of micronuclei was observed by all three compounds (Table 1 in III). By the 
highest concentrations tested, C1 (1000 nM) and TCDD (100 nM), elicited fold-
increases of 1.82 and 1.58 over negative controls, respectively. However, the Cochran-
Armitage test of trend did not quite show statistical significance for C1 and TCDD (p 
t 0.068). C3 induced a maximal fold-increase of 2.67 by the highest dose of 1000 nM, 
and showed a statistically significant linear trend (p=0.001), with the proportion of 
cells containing micronuclei increasing as a function of concentration. The positive 
control mitomycin c (500 nM) induced a fold-increase of 10.44 in frequency of 
micronuclei. 
5.1.2 Acute and subacute toxicity in SD rats (II) 
Clinical signs of toxicity. No clinical signs of toxicity were seen during the acute 
toxicity experiment with either of the test compounds, or at any dose level tested. The 
same applied in the subacute toxicity experiment after 5-day dosing at high dose 
levels, except for peculiar, transient hyperaemia of the ear pinnae observed in both 
test compound groups (Supplementary Fig. 1 in II). This change appeared on the first 
day after the end of the dosing regimen and persisted for 3–4 days.  
Contrary to the characteristic wasting syndrome of TCDD, BW gain tended to be 
only marginally decelerated in both experiments (Fig. 3 and Supplementary Table 2 
in II). In the acute toxicity study, at 7 days post-exposure, a slightly delayed BW gain 
trend reached statistical significance (p < 0.05) only for the high-dose C4 group 
compared with the controls. In the subacute toxicity study, two-way mixed ANOVA 
revealed a statistically significant interaction in BW gain between treatment and time 
(F[4,28] = 3.647; p = 0.016; partial η2 = 0.343), and subsequent univariate ANOVAs 
(followed by the Tukey HSD tests) at the three time points showed that the BW gain 
of C2 at 9 days (4.7%) was lower than that of the controls (10.1%; p = 0.049). 
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Organ weights. Both relative and absolute thymus weights exhibited a decreasing 
trend in the acute toxicity study, with a statistically significant (p < 0.05) relative 
weight loss of 30% in both C2 and C4 high-dose groups compared with the controls 
(Supplementary Table 2 in II). This effect was confirmed in the subacute toxicity 
study, where the relative weights were about 40% lower in both groups than in the 
control group (40% for C2, and 36% for the C4 group; one-way ANOVA, p < 0.001; 
Fig. 5). In the other organs sampled (liver, kidneys, spleen and testes), there were no 
statistically significant changes among groups.  
 
Clinical chemistry. Clinical chemistry variables from serum were only analysed 
following the subacute toxicity study. The only marked alteration was a reduction of 
triglycerides by C2 (44%, p = 0.02; Fig. 7 in II). C4 had a similar effect, but the 30% 
decrease caused by it did not reach statistical significance. In addition, there was a 
statistically significant increase of 86% in the level of 3-HB by C4 (p = 0.045). A 
similar increase of 58% by C2 was not statistically significant. 
 
Thyroxine level measurement. There were no statistically significant differences 
in thyroxine (T4) levels among the groups (p = 0.426; Supplementary Table 4 in II). 
 
Retinoid analysis. Analysis of polar and apolar retinoid concentrations in the 
serum, liver and kidney was performed for the control, C2 and C4 groups after the 
subacute toxicity experiment. Overall changes in retinoid concentrations are 
presented in Table 5. The magnitudes of these effects were largely comparable 
between C2 and C4 (Table 2 in II). For most retinoid forms analysed, the changes 
recorded were slightly more pronounced in the C2 vs C4 group, in line with the higher 
administered dose of this compound. Two exceptions to this rule were provided by 
renal retinyl palmitate and serum 13-cis-retinoic acid concentrations, which were 
clearly more affected by C4 than C2.  
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Table 5. Statistically significant mean changes in retinoid concentrations by C2 (100 
mg/kg/day) and C4 (75 mg/kg/day) in the subacute toxicity study (II), presented 
as fold changes over controls. P < 0.05, one-way ANOVA followed by linear 
contrast test. 
Retinoid Serum Liver Kidney 
C2 C4 C2 C4 C2 C4 
All-trans retinoic acid − − 1.3 − 1.3 − 
Retinol 1.3 1.2 − − 1.3 1.3 
Retinyl palmitate 0.5 0.6 0.6 0.7 2.4 3.3 
9-cis-4-oxo-13,14-dihydro-retinoic acid 0.4 0.6 0.1 0.1 − − 
13-cis-retinoic acid 0.5 0.4 − − nd nd 
4-hydroxy-all-trans-retinoic acid nd nd 0.3 0.3 nd nd 
− = statistically not significant 
nd = not detected 
 
 
Histopathology. Histopathology was not examined in the acute toxicity study, 
whereas in the subacute toxicity study, the liver, spleen, kidney, lung and testis were 
investigated. The only, very mild reaction was observed in the liver, where both C2 
and C4 administration induced minimal hepatic extramedullary myeloid 
haematopoiesis (EMH; Fig. 6 in II) (Thoolen et al. 2010). This was observed in 3/5 
C2-treated and in 4/5 C4-treated animals; none was present in controls. 
5.1.3 Changes in the expression of AHR-battery genes (I−III) 
CYP1A1 enzyme activity in vitro (II, III). C1 and C3 were tested in vitro in the 
H4IIE rat hepatoma cell line for their CYP1A1 enzyme induction potential, which was 
compared with that of TCDD. Exposure times were 24 h in II and 48 h in III. 
In II, all of the compounds showed a statistically significant induction of CYP1A1 
(ANOVA, p < 0.005), which increased in a dose-dependent fashion (Fig. 8 in II). 
Apart from the lowest dose level of 1 nM, each concentration of the compounds 
increased CYP1A1 induction in a statistically significant manner when compared with 
the control group. 
In III, both C1 and C3 were likewise very effective and potent activators of CYP1A1 
(Figure 4 in III). The potencies of all three compounds were similar: compared with 
the controls, C1 and C3 induced CYP1A1 statistically significantly at concentrations of 
100 pM and above (p ≤ 0.009 for C1 and p ≤ 0.013 for C3), and TCDD from 500 pM 
on (p ≤ 0.008). However, TCDD was the most potent inducer of the three. At 500 pM, 
the induction by TCDD was already more intense than by C1 and C3, attaining a 50-
fold difference compared with the controls, while for C1 and C3, the respective fold 
changes were 10 and 20. The EC50 values for C1, C3 and TCDD were 24.1, 35.9 and 
1.0 nM, respectively. The induction potential of TCDD peaked at 50 nM and appeared 
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to level off after that. Interestingly, compared with TCDD, both C1 and C3 attained an 
equivalent or even higher maximum induction of CYP1A1 at the highest concentration 
tested (1000 nM). Furthermore, it appears that the maximum response with C1 and 
C3 may not have been reached at 1000 nM, and therefore C3, and possibly also C1, 
have even higher efficacies than TCDD. 
Furthermore, the ability of the selective AHR antagonist CH-223191 to block 
CYP1A1 induction by C1 and TCDD was tested with exposure times of 24 h and 48 h. 
At a concentration of 100 nM, CH-223191 was able to completely block the effect of 1 
nM C1 and TCDD at both time points (Figure 5 in III).  
 
Cyp1a1 gene induction in vivo (I, II). In I, there was a clear and statistically 
significant induction of hepatic Cyp1a1 induction by single doses of C2 at all three 
dose levels tested (p < 0.05; Table 6). Even the lowest tested dose of 4 mg/kg induced 
Cyp1a1 expression by 1700-fold at 28 h after exposure, a strong early response 
compared with the 350-fold increase brought about by a high, lethal dose of 0.1 mg/kg 
TCDD in L-E rats at 24 h in a previous study (Lindén et al. 2014). 
However, while the response induced by TCDD intensifies during some days 
following exposure, the same did not apply for C2. After single doses of 20 and 100 
mg/kg, hepatic Cyp1a1 induction fold changes at 48 h and 72 h, respectively, were 
down to a ~100-fold increase compared with controls (Table 6). Likewise, in II, after 
5-day repeated dosing at high dose levels, followed by 5 days of recovery before 
sampling, Cyp1a1 induction by C2 and C4 was less pronounced than that at day 10 
following a single dose of TCDD. 
In addition to hepatic Cyp1a1 induction, there was substantial Cyp1a1 induction 
by C2 in all of the other tissues examined in II, and, apart from the testis, also by C4 
(p < 0.05; Fig. 4 in II). 
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Table 6. Statistically significant hepatic inductions of selected AHR-battery genes by C2, 
C4 and TCDD, expressed as fold changes over controls. C2 and C4 were 
administered to SD rats for 5 consecutive days, unless otherwise specified. 
TCDD was administered once to L-E rats1. P < 0.05, one-way ANOVA/Student-
Newman-Keuls or Student’s t-test. 
Gene Sampling time  
(days post-
exposure) 
C2 
100 mg/kg/day 
(differing dosing) 
C4 
75 mg/kg/day 
TCDD2 
100 μg/kg once 
Cyp1a1 1 1700 
(4 mg/kg once) 
na 350 
2 100 
(20 mg/kg once) 
na na 
3 130 
(100 mg/kg once) 
na na 
10 370 140 1100 
Cyp1a2 10 5 2 8 
Cyp1b1 10 5 − 1600 
Ahrr 10 6 3 230 
Nqo1 10 3 − 50 
Tiparp 10 − − 25 
Ugt1 10 1.4 − 7 
na = not analysed 
1 Comparison between SD and L-E strains is considered justified, as the AHR-mediated induction of 
xenobiotic-metabolising enzymes is exhibited in the same fashion by all rat strains (M. A. Franc et al. 
2008). 
2 The samples for the TCDD groups were from a study by Lindén et al. (2014), where TCDD-sensitive 
L-E rats were exposed to a single ig dose of 100 μg/kg TCDD, and necropsied at 10 days. The cDNA 
for these samples had been reverse-transcribed previously, but qPCR was performed with the same 
primers and in the same conditions as for C2 and C4 for comparison. 
 
 
 
Induction of other selected AHR-battery genes in vivo (II, III). In addition 
to Cyp1a1, hepatic mRNA abundances of Cyp1a2, Cyp1b1, Cyp2b1, Ahrr, Nqo1, 
Tiparp and Ugt1a were determined in the repeated C2 and C4 exposure experiment 
(II). Overall, the inductions observed after C2/C4 exposures were much less 
pronounced than after exposure to TCDD (Table 6). The most conspicuous 
differences in the induction profiles of TCDD and C2/C4 were discernible in Cyp1b1, 
Ahrr, Nqo1 and Tiparp, all of which were markedly induced by TCDD but feebly, if at 
all, by C2/C4. 
5.1.4 Molecular docking analysis (III) 
Simulation of ligand binding by molecular docking to the homology model of the rat 
AHR LBD predicted that the binding geometries as well as the protein–ligand 
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interactions of both C1 and C3 are similar to those of TCDD (Figure 6 in III). In fact, 
both compounds show mostly planar conformations in the docked poses, like TCDD, 
and occupy the central region of the ligand binding cavity (Figures 6b and 6c in III), 
similarly to what has been predicted for TCDD (Figure 6a in III) in the high-affinity 
mouse and rat AHRs (Motto et al. 2011). Most of the ligand-protein interactions that 
stabilize the C1 and C3 complexes are the same for the two ligands and cause similar 
binding affinities for the AHR. Stabilization is mainly due to hydrophobic interactions 
with residues within the binding cavity and to a hydrogen-bond with a central 
glutamine residue. 
5.2 Novel food avoidance behaviour 
5.2.1 Ability of AHR agonists to induce novel food avoidance (I) 
All of the tested AHR agonists, FICZ, BNF and BaP, induced practically total 
abstinence from the consumption of chocolate (Figure 9). However, the duration of 
the effect varied: ~1 day for FICZ, 2–3 days for BNF and 3–4 days for BaP. The 
duration of the effect was assessed based on behavioural observation; the limit for 
fading of the avoidance was set at ~3 g of daily chocolate consumption, as 3 g was 
about half of the amount the controls consumed in the first 24 h post-exposure, and 
also roughly the amount after which consumption started increasing quite rapidly. 
Similarly, C2 also induced total avoidance of the novel food at all the tested dose 
levels (Figure 9). At 100 mg/kg, the effect persisted for 2–3 days. The 4 and 20 mg/kg 
dose groups were only monitored for up to 24 and 48 h, respectively, until which the 
effect persisted. The animals in these groups were euthanized and sampled before the 
avoidance had passed to ensure that activation of AHR could be verified. 
71 
6 24 48 72
C
on
su
m
pt
io
n 
(g
)
0
10
20
30
Control 
FICZ 
BNF 
BaP 
C2 (4 mg/kg) 
C2 (20 mg/kg) 
C2 (100 mg/kg) 
Time post-exposure (h)  
Figure 9. Cumulative consumption of chocolate after single doses of FICZ (0.1 mg/kg), 
BNF (60 mg/kg), BaP (150 mg/kg), C2 (4, 20, and 100 mg/kg) or the vehicle 
(mean + SD; n = 6 in all groups, except 12 in controls, both individual 
experiments combined). The reference line marks the consumption of 3 g, which 
was considered the limit value for the end of the avoidance phase. Chocolate 
consumption in the C2 4 mg/kg and 20 mg/kg groups was measured for only 24 
and 48 h, respectively, in order to verify Cyp1a1 induction. 
5.2.2 Dependence of the response on the AHR (I, unpublished) 
In I, the CAR activator TPD caused a robust and sustained hepatic induction of 
Cyp2b1 expression (about 1000-fold; Table 1 in I), but in contrast to the results 
obtained with the AHR agonists tested, it did not influence chocolate consumption at 
all. By 24 h post-exposure, the TPD-exposed rats consumed 6.8 g (± 2.2 g) of 
chocolate, whereas the corresponding consumption in the control group was 6.2 g (± 
3.0 g; Fig. 3 in I). Furthermore, TPD did not induce the genes of the AHR battery 
examined, apart from a tiny (3.3-fold) enhancement of hepatic Cyp1a1 expression 
(Table 1 in I). Interestingly, there was one outlier rat in the TPD group that consumed 
practically no chocolate (0.3 g) during the 24 h of monitoring, exhibiting avoidance 
comparable to that in the BNF and BaP groups. RT-qPCR analysis revealed that while 
this individual’s Cyp2b1 induction in the liver and duodenum was similar to that in 
the rest of the TPD group (Table 1 in I), Cyp1a1 was induced 300-fold in the stomach. 
Furthermore, in I, both AHR-antagonists, CH-223191 and GNF351, failed to 
alleviate FICZ-induced novel food avoidance behaviour. It is noteworthy, however, 
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that both antagonists, administered separately ig as single doses (13 mg/kg of CH-
223191 or 5 mg/kg of GNF-351), also failed to modify Cyp1a1 gene induction caused 
by FICZ. Similarly, a single dose of CH-223191 failed to modify both Cyp1a1 induction 
and avoidance behaviour by C2. 
Moreover, in an unpublished experiment, AHRKO and littermate WT SD rats 
were employed for novel food avoidance response studies. The AHRKO genotype of 
this rat line was verified as AHR deficient by examining hepatic Cyp1a1 expression 
levels following single BNF exposures (6o mg/kg, ig). As expected, the Cyp1a1 gene 
was not expressed in the AHRKO rats or induced in them by BNF, contrary to the WT 
lineage (Figure 10). 
In the first experiment conducted with the AHRKO rat line, the study design was 
identical to that used previously, and novel chocolate was placed in the cages directly 
after exposures. However, both genotypes behaved differently compared to the 
Harlan SD rat line used in the previous experiments, as the controls exhibited a 
considerably slower onset of chocolate consumption than before. By 24 h, the WT and 
KO control group consumption averages were 1.6 r 2.4 g and 1.9 r 2.9 g, respectively. 
Despite this, by 48 h, it appeared evident that unlike in WT rats, BNF did not induce 
avoidance behaviour in the KO rats, although the low number of animals 
(n = 3/group) constrained the interpretation of this result. The WT control and BNF 
groups had consumed on average 13.3 r 5.9 g and 1.2 r 0.9 g of chocolate, respectively, 
while in the KO rats, the respective control and BNF group chocolate consumptions 
were 5.8 r 6.7 g and 9.3 r 3.8 g. 
In the second experiment with the AHRKO rat line, chocolate was placed in each 
cage for ~24 h prior to exposures. Chocolate consumption during the first 24 h before 
exposures was 9.2 r 1.8 g and 7.9 r 1.7 g in the WT and KO lines, respectively. After 
exposures, as hypothesised, BNF failed to influence chocolate intake in the KOs; both 
the control and BNF groups consumed on average 6.3–6.6 g by 24 h (p = 0.875; 
Figure 10). In contrast, in the WT lineage, BNF-treated rats exhibited clear chocolate 
avoidance, while the controls did not (respective 24-h consumptions: 1.3 vs 8.3 g, 
p = 0.011; Figure 10). 
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Figure 10. Left panel: 24-h cumulative consumption of chocolate (mean + SD; n = 6–7) 
after a single dose of BNF (60 mg/kg) or vehicle in WT and KO rats. The groups 
differing from each other in a statistically significant fashion are marked with an 
asterisk (p < 0.05). Right panel: Hepatic Cyp1a1 expression (mean + SD, 
logarithmic scale) within both genotypes, confirming that the KO line is AHR 
deficient. The BNF groups differing in a statistically significant manner from their 
controls, within each genotype, are marked with an asterisk (p < 0.05). 
5.2.3 Persistence of the effect in the absence of novel food (I) 
Similarly to previous experiments, during the initial 6-h period post-exposure, the 
AHR-agonist-treated rats nibbled only minute amounts of chocolate, if any (Fig. 4A 
in I), after which it was removed from the cages. At the re-introduction two weeks 
later, both AHR activators still provoked the avoidance of chocolate, which resembled 
that of the first encounter in the earlier studies. While controls reached the set limit 
value of 3 g chocolate intake by approximately 6 h, for rats treated with FICZ or BNF, 
this took 6–24 h or 24–48 h, respectively (Fig. 4A in I). 
5.2.4 Effect of vagotomy on the avoidance response (unpublished) 
Vagotomy did not prevent the emergence of the novel food avoidance behaviour in 
the AHR-agonist-treated group. By 48 h post-exposure, rats in the control group 
consumed an average of 8.6 ± 2.2 g of chocolate, while rats in the BNF group exhibited 
clear avoidance, consuming only 0.3 ± 0.2 g of chocolate (p = 0.02). 
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6 DISCUSSION 
The AHR is a transcription factor involved in numerous functions within organisms, 
and imparts both beneficial physiological and harmful adverse effects. The 
mechanisms are highly diverse and complex, and currently incompletely understood. 
In addition to conveying the toxicity of environmental contaminants, such as dioxins, 
it appears that inappropriate modulation of the AHR has a role in the pathogenesis of 
several illnesses. Therefore, it is also an intriguing target for pharmacological 
research. So far, the AHR has mostly been considered as a potential target for 
treatment of immunological diseases and cancer. However, it is quite possible that we 
are not yet aware of all its functions, and the AHR could therefore also be employed 
as a target for the treatment of other types of diseases and conditions. 
As lead compound candidates for drug development, SAHRMs are particularly 
interesting, as they only produce subsets of AHR-mediated effects. Therefore, they 
could conceivably be optimised with the aim of producing beneficial effects of AHR 
modulation, omitting toxicity. 
Furthermore, SAHRMs could be valuable tools in further elucidating the so far 
incompetently understood, multifaceted physiological roles and effects of the AHR, 
and the underlying molecular mechanisms and pathways. Increasing information on 
them could also help us understand the aetiology and pathogenesis of adverse 
outcomes that we are currently only attempting to characterise, such as the effects 
that the increasing amounts of chemicals in our environment may have on our health. 
This thesis research examined the toxicity of two novel SAHRMs, intended as 
potential drug compounds. It also further characterised a peculiar novel food 
avoidance behaviour in rats, which had previously been described following TCDD 
exposure. 
6.1 Effects of the novel SAHRMs 
Previously, very limited experimental information was available about the novel pro-
drugs C2 and C4 and their active metabolites, the SAHRMs C1 and C3. The few earlier 
studies had primarily aimed at exploring their pharmacological potential, which had 
proven promising. In the EAE model in rats, a total dose of 4 mg/kg C2 (sc) had 
efficiently prevented EAE development (Pettersson 2012). It had also had an 
ameliorating effect in the dextran sulfate sodium-induced colitis model in mice, at a 
dose of 1 mg/kg (po; unpublished data). 
In this study, selected toxicological properties of these compounds were 
examined. Their effectiveness and potency in activating the AHR were also 
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characterised and compared with TCDD. Furthermore, the binding of the three 
compounds to the rat AHR was explored in silico. 
6.1.1 AHR-activation potential and binding to the AHR (I–III) 
To study the potency and efficacy of C1 and C3 as AHR activators in vitro, the 
metabolically active H4IIE rat hepatoma cell line was employed and the novel 
compounds compared with TCDD. The AHR-activating potential was assessed as 
induction of the xenobiotic-metabolising enzyme CYP1A1, as it is sensitive biomarker 
of AHR activation (Abraham et al. 1988). 
Screening of the compounds in II revealed that both novel SAHRMs, C1 and C3, 
induced responses quite similar to that of TCDD. Closer scrutiny in III reinforced the 
results, and showed that both compounds are similar to TCDD in their efficacy and 
potency of AHR activation. The latter experiments also confirmed that C3 appears to 
be the somewhat more effective compound of the two. However, it should be noted 
that only a continuous hepatoma cell line was used in these experiments. Including 
normal cells would have strengthened the investigation, and possibly given more 
robust information, as their physiology better reflects that of healthy organisms. 
The in vitro results were furthermore supported by the in vivo data on Cyp1a1 
gene induction in I, which demonstrated that C2 is a highly effective inducer of the 
Cyp1a1 gene following single doses at several dose levels (Table 6). However, while 
the response with TCDD intensifies during some days following exposure, the same 
does not apply for C2. Therefore, it appears that unlike TCDD, C2 and C4 are rapidly 
metabolised in rats, with an elimination half-life within the range of hours to a couple 
of days. However, the potent Cyp1a1-induction by C2 at one day post-exposure 
implies that also in vivo, the inherent effectiveness of C2 may be, at minimum, 
comparable to that of TCDD. 
In addition to Cyp1a1, both C2 and C4 also induced several other AHR-battery 
genes of xenobiotic metabolism, but the induction profiles were distinct from that of 
TCDD (Table 6), indeed suggesting selective modulation. 
Furthermore, in III, the ability of C1 and C3 to bind the rat AHR was studied by in 
silico methods, in comparison with TCDD. The simulations revealed that the binding 
geometries of C1 and C3 are similar to those of TCDD, and that both ligands adopt 
mostly planar conformations in the docked poses. Interestingly, most of the residues 
involved in the stabilization of C1 and C3 belong to the group of highly conserved 
residues lining the binding cavities of several mammalian AHRs, and are necessary 
for optimal TCDD binding (Motto et al. 2011, Pandini et al. 2009). Therefore, the 
computational results support the hypothesis that these novel SAHRMs effectively 
bind to the AHR and act as its agonists. 
This conclusion is supported by the in vitro finding in III that the AHR antagonist 
CH-223191, reported to only be a selective antagonist of dioxin-like AHR activators 
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(S. -. Kim et al. 2006, Zhao et al. 2010), was able to block CYP1A1 induction by C1 as 
efficiently as that of TCDD. This further supports the view that at least C1 binds to the 
LBD of the AHR in a manner similar to that of TCDD. 
6.1.2 Toxicity in vitro and in vivo (II, III) 
In vitro toxicity. In vitro toxicity testing was employed to provide initial 
predictions of possible toxic effects in vivo. In this study, C1 and C3 were examined 
for their potential to induce cytotoxicity in the LDH leakage assay, their effect on 
metabolic activity in the MTT reduction assay, and their genotoxicity in the Ames test 
and in the micronucleus assay. 
In III, the novel SAHRMs, like TCDD, were not cytotoxic, as assessed by the LDH 
leakage assay. However, while being a robust method and widely used, the LDH assay 
only detects cytotoxicity following damage to the cell membrane, as LDH is released 
from the cytosol. Therefore, it does not identify compounds that reduce viability 
through other pathways. Thus, C1, C3 and TCDD were also tested using the MTT 
reduction assay. In the MTT reduction assay, dose-dependent reductions in metabolic 
activities were observed by all three compounds. However, the effects of C1 and C3 
did not intensify dramatically between 6 h and 24 h, in contrast to the result following 
TCDD exposure. Furthermore, the cells treated with C1 and C3 appeared to have even 
slightly recovered at concentrations up 100 nM by 24 h. By this time point, TCDD 
reduced metabolic activity at a ≥ 10-fold lower concentration of 100 nM than C1 or 
C3. Therefore, considering that the EC50 values for C1 and C3 were found to be 24 
and 36 nM, respectively, and that metabolic activity was down to only a80% of vehicle 
control activity even with the highest concentrations of 1000 nM tested, C1 and C3 do 
not appear cytotoxic in the MTT reduction assay. Furthermore, these results support 
the view that C1 and C3 are rapidly metabolised to inactive products, unlike TCDD. 
The Salmonella Typhimurium strains used in the Ames test were TA98 and 
TA100, which contain the hisD3052 and hisG46 mutations, respectively (Maron and 
Ames 1983). The TA98 strain primarily detects mutagens that cause frameshift 
mutations, while the TA100 preferentially detects mutagens causing base-pair 
substitutions. Only C1 and C3 were tested here, as it has been previously shown that 
TCDD is not mutagenic (Thornton et al. 2001). Similarly to TCDD, neither C1 nor C3 
were mutagenic in the Ames test. However, at doses of !20 μM for C1 and at !70 μM 
for C3, the compounds appeared cytotoxic in the TA98 strain. Nevertheless, the 
highest tested plate concentrations of 1 mM can be considered the maximum 
achievable due to precipitation on the plates at that dose level. Therefore, and despite 
some limitations in the efficiency of the S9 mix, the negative result in the Ames test 
can be considered reliable for both compounds, particularly in the TA100 strain. It 
thus appears that in the Ames test, C1 and C3 do not induce base-pair substitutions 
and are unlikely to induce frameshift mutations. 
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Yet, in the micronucleus assay, C3 induced a statistically significant, increasing 
trend in number of micronuclei, while C1 and TCDD showed a tendency for statistical 
significance. The significance of the positive effect by C3 is unclear, however, 
particularly considering the small magnitude of the fold-increase vs. the positive 
control mitomycin c, and the similar result obtained with TCDD. This is due to TCDD 
being known to not be a genotoxicant in vivo (Huff et al. 1991, Meyne et al. 1985, 
Nebert et al. 2004), even though particularly in vitro, it has occasionally appeared 
positive at high concentrations in genotoxicity tests, including a micronucleus test in 
rat hepatocytes (Turkez et al. 2014). Therefore, in order to conclude whether the 
effect seen here with C3 is relevant, an in vivo micronucleus test may be necessary. 
Only one cell line was employed in the in vitro experiments, apart from the Ames 
test where two strains were used. The H4IIE was selected for its exceptional metabolic 
activity (Fujimura et al. 2012) and because it has been shown to be very responsive to 
dioxins (Bradlaw and Casterline Jr. 1979, Sawyer and Safe 1982). Nevertheless, the 
investigation would have been strengthened by repeating the experiments with other 
cell lines, as different lines typically respond, at least to some extent, differentially 
under the same conditions. Including a normal cell line would have furthermore 
strengthened the information about the in vitro effects of these compounds. 
However, the methods used are generally considered robust for the purpose of 
screening compounds, and overall it can be concluded that apart from the equivocal 
result of the micronucleus test, the results from in vitro testing do not raise concern 
for toxicity in vivo. 
 
In vivo toxicity. In vivo, C2 and C4 were studied for toxicity in male SD rats in II, 
first after acute dosing and then after 5-day repeated dosing. TCDD was not tested 
here, but results from the literature were used to compare the effects. 
The single dose experiment confirmed that the acute toxicity of the compounds 
was low, even at the highest doses practically achievable, which were 100 mg/kg for 
C2 and 75 mg/kg for C4. During the experiment, there were no apparent clinical signs 
of toxicity, and the compounds were therefore deemed suitable for repeated 
administration. However, thymus size was significantly diminished by single high 
doses of both compounds, and a tendency towards dampened growth was observed 
with the high dose of C4. Nevertheless, because the numbers of animals used at each 
dose level in this experiment were low (n = 1–3), the results were regarded as 
indicative. 
In the repeated-dosing study, C2 and C4 were tested at only one dose level each 
due to a shortage of available resources. The undesirable consequence of this 
limitation was that the study design did not allow investigating the dose-dependency 
of the observed effects. The doses used were 100 mg/kg/day for C2 and 75 mg/kg/day 
for C4 on five consecutive days, followed by a 5-day monitoring period. The exposure 
period was short, but as the doses were high, the study can be expected to have 
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revealed the short-term toxic potential of the test compounds, particularly for any 
sensitive endpoints.  
The rats tolerated the treatments well overall also following repeated dosing, even 
though the compounds were not without effects. Interestingly, the profiles of C2 and 
C4 appeared distinct from that of TCDD, supporting the view that these compounds 
are truly selective; both C2 and C4 lacked some of the major characteristic toxic effects 
of TCDD, shared some with it, but also exhibited a small number of adverse effects 
not seen with TCDD, all presented in Table 7. 
Of the characteristic toxic effects of TCDD that were lacking with C2 and C4 in this 
study, lethality and wasting syndrome are perhaps the most notable. Considering that 
C2, C4, and TCDD also appear to be similarly effective as inducers of Cyp1a1 in vivo, 
it is noteworthy that each C2 and C4 dose of 75–100 mg/kg/day, administered on five 
days, was 1500–2000 times higher than the TCDD LD50 of ~50 μg/kg in the SD 
strain (M. Franc et al. 2001). However, only a slight downward tendency was 
recorded in BWs following C2 and C4 administration. While, as already established, 
C2 and C4 appear to be metabolised much more rapidly than TCDD, it does not 
appear plausible that merely a difference in kinetics could explain such a drastic 
difference in the toxic effects. 
Nevertheless, two characteristic adverse effects of TCDD were also observed with 
C2 and C4, although somewhat less pronounced: thymic atrophy and changes in 
tissue retinoid (vitamin A) concentrations (Fletcher et al. 2001, Gupta et al. 1973, M. 
W. Harris et al. 1973). The occurrence of thymic atrophy is particularly interesting, as 
it is one of the most consistent and uniform effects of TCDD across mammalian 
species (Pohjanvirta and Tuomisto 1994). However, the toxicological relevance of this 
effect in adults, rodents or humans, is unclear, as thymus function is mostly relevant 
during the prenatal period, and physiological atrophy of the thymus ensues by 
adolescence. Furthermore, the thymus does not appear to be involved in dioxin-
induced immunotoxicity (Kerkvliet and Brauner 1987).  
As to retinoid homeostasis, no firm conclusions can yet be drawn on the full extent 
to which the alterations induced by C2 and C4 resemble those of TCDD, as there are 
not enough data in the literature on the effects of TCDD on several of the retinoic acid 
derivatives in the tissues that were analysed in this study. However, some of the 
hepatic and renal changes induced by C2 and C4 were reminiscent of those seen after 
short-term TCDD exposure in male rats (Hoegberg et al. 2003, Nilsson et al. 2000, 
C. K. Schmidt et al. 2003), while others seen in C2- and C4-treated rats were not 
typical effects of TCDD. Moreover, high TCDD doses have been reported to induce 
changes that remained unaltered following C2 or C4 exposure. More information is 
therefore needed on these changes to evaluate their significance. 
Moreover, some characteristic adverse effects common to TCDD exposure were 
not considered in these experiments due to technical reasons, and thus information 
on the effects of C2 and C4 on these is, for the time being, lacking completely. These 
include further effects on the endocrine system, such as changes in testosterone, 
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insulin or melatonin levels, changes in the degree of oxidative stress in various tissues, 
bone and tooth lesions, immuno- and developmental toxicity, and carcinogenicity. 
The occurrence of all of these should naturally be tested in the future. 
Altogether, C2 and C4 brought about only a subset of the studied response 
spectrum previously reported with TCDD (Table 7), and all these effects belong to the 
type I category (Pohjanvirta et al. 2011). The effects in this category are robust to 
structural variations in the AHR transactivation domain, and thereby represent more 
generic AHR-mediated impacts. Whether any of type II responses, such as wasting 
syndrome, would manifest during longer exposure periods or if higher doses of C2 or 
C4 could be administered is a matter of speculation and should be studied further. 
However, the slight downward tendency recorded in BWs in the present study might 
suggest that the existence of early alterations in the adverse outcome pathway that 
ultimately culminates in the wasting syndrome cannot be entirely ruled out. 
 
Table 7. Selected type I and II responses typical after a single high dose of TCDD 
(Pohjanvirta and Tuomisto 1994, Pohjanvirta et al. 2011, Viluksela et al. 1999), 
and their occurrence in SD rats after repeated 5-day dosing with C2 (100 
mg/kg/day) and C4 (75 mg/kg/day), followed by a 5-day monitoring period. 
Furthermore, effects of C2 and C4 not seen after TCDD exposure are presented. 
Type Effect TCDD C2 C4 
I Induction of Cyp1a1 gene + + + 
 Induction of all studied AHR-battery genes + – – 
 Thymus atrophy + + + 
 Changes in retinoid homeostasis + + + 
 Hypercholesterolaemia + – – 
 Reduced plasma thyroxine levels + – – 
 Novel food avoidance behaviour + + na 
II Lethality + – – 
 Wasting syndrome + – – 
 Grave liver lesions + – – 
 Testis lesions + – – 
 Hypoglycaemia + – – 
 Elevated plasma FFA levels + – – 
– Ear hyperaemia – + + 
– Minimal hepatic EMH – + + 
– Reduction of serum triglycerides – + (+) 
– Increase of serum 3-HB – (+) + 
+ = present; – = lacking; na = not assessed, (+) = present, but not statistically significant 
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In addition to the two adverse effects typical of TCDD, C2 and C4 also induced effects 
that have not been reported with TCDD, presented in Table 7. Of these, ear 
hyperaemia was perplexing and unexpected, and should be further examined in 
future studies. EMH refers to haematopoiesis occurring outside of the medullary 
spaces of the bone marrow (Johns and Christopher 2012, C. Kim 2010). It is mostly 
considered to lack serious clinical or diagnostic implications, and can occur without 
any obvious underlying cause or consequences. Therefore, and as the hepatic EMH 
seen in this study was minimal, it may not imply any relevant toxicity. However, its 
possible recurrence should not be overlooked in future studies with these compounds, 
as EMH can occur secondary to, for instance, local hypoxia, bone marrow 
insufficiency and myelotoxicity (Chiu et al. 2015). As to the observed changes in 
clinical chemistry, the decrease in triglycerides and elevation of 3-HB point to 
enhanced β-oxidation and lowered de novo fatty acid biosynthesis in the liver, which 
could in fact be interpreted as beneficial effects. 
 
Most AHR ligands bind to the receptor with moderate or low affinities compared to 
TCDD, and most of them also have lower abilities to induce CYP1A1 (Safe et al. 2011). 
The novel SAHRMs studied here, however, were predicted in silico to possess binding 
affinities similar to that of TCDD, and they are almost similarly effective inducers of 
CYP1A1 in vitro and Cyp1a1 in vivo. Based on in silico modelling, they also appear to 
bind to the rat AHR in a manner similar to that of TCDD. However, the compounds 
show markedly less toxicity in vivo in rats, both after acute and repeated 5-day dosing. 
Nevertheless, they were not completely without adverse effects, although none of 
them appeared grave. Importantly, considering the effectiveness of these novel 
SAHRMs, the doses used in this study can be regarded to have been very high. Thus, 
as they are apparently truly selective in their effects, these SAHRMs appear 
interesting candidates for therapeutic uses. They may also have wider implications 
for AHR research, and could be valuable tools in further elucidating the multifaceted 
physiological roles of the AHR and the underlying molecular mechanisms. 
In the future, it would be important to further characterise the toxicological effects 
of these compounds. In particular, because they appear to be metabolised rapidly but 
are potent and effective AHR activators, it would be crucial to investigate whether 
prolonged exposure to C2 and C4 in vivo would elicit more pronounced toxicity than 
seen here. In addition, examining their kinetics and elimination rate in rats would 
give important information, as well as a comparative metabolism study in rat and 
human normal hepatocytes. Furthermore, it will be vital to study these compounds in 
representative human cell cultures and micro tissues, as these results are limited to 
rats. As previously discussed, different AHR agonists commonly exert varying effects 
among species, complicating extrapolation between species. However, as these 
compounds elicited only type I responses of TCDD, previously demonstrated to be 
largely indifferent to structural variation at the transactivation domain of the AHR in 
TCDD-treated rats (Pohjanvirta et al. 2011), pre-clinical data with these compounds 
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could arguably also be reasonably relevant to human hazard assessment, unless type 
II effects also emerge during prolonged exposure or at higher doses. Moreover, if 
future binding modelling would reveal that C1 and C3 are also bound to the human 
AHR in a manner similar to that of TCDD, it is conceivable that their toxic effects 
would be less pronounced in humans than in rats, as humans appear to be less 
sensitive to TCDD than most rat strains. This outcome would naturally also be likely 
to improve the prospects of employing these SAHRMs as safe or tolerable drug 
compounds. Finally, it would be highly interesting to analyse their effects on the 
whole transcriptome by RNA sequencing in order to thoroughly assess their 
similarities and differences with TCDD. 
6.2 The AHR and novel food avoidance (I, unpublished) 
Previously, it was discovered that concurrent exposure to TCDD and presentation of 
novel food items caused rats and mice to exhibit strong and persistent dislike towards 
novel foods (Lensu et al. 2011a, Lensu et al. 2011b, J. T. Tuomisto et al. 2000). 
Moreover, there appeared to be a correlation between ED50 values for the induction 
of hepatic CYP1A1 and novel food avoidance. The critical participation of the AHR in 
this bizarre effect appeared likely, as virtually all biological effects of TCDD require 
AHR modulation, and the avoidance was not seen in AHRKO mice. Furthermore, 
since AHR signalling is the predominant up-regulator of Cyp1a1 gene expression (Q. 
Ma 2001), the finding suggested a possibility of a causal relationship between hepatic 
AHR activation and the behavioural change (Lensu et al. 2011b). 
However, interpretation of the results in KO mice had been somewhat hampered 
by the unexpected finding that consumption of the novel food was higher in the 
TCDD-treated than in the vehicle-treated group (Lensu et al. 2011b). Furthermore, 
the early experiments did not explore whether this effect was only related to TCDD, 
more generally to the induction of xenobiotic metabolism, or specifically to activation 
of the AHR. Therefore, in this study, it was set out to further investigate the 
involvement of the AHR in novel food avoidance behaviour in rats, in which this 
response had been found to be more pronounced than in mice following TCDD 
exposure (Lensu et al. 2011b). 
6.2.1 Dependence of the response on the AHR 
In I, it was established that the induction of novel food avoidance behaviour was 
not limited to TCDD, but also occurred with all of the other AHR agonists tested, 
FICZ, BNF and BaP. FICZ, BNF and BaP were each only studied at one dose level, and 
therefore dose response could not be considered. Interestingly, the SAHRM C2 was 
also shown to induce novel food avoidance. With C2, it appears likely that the lowest 
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effect level would be considerably beneath the lowest tested dose of 4 mg/kg, based 
on the strong response. The high potency of C2 probably explains why no dose-
response was observed, despite of testing at three dose levels. 
Furthermore, in two currently unpublished experiments, the novel food avoidance 
behaviour was not seen in AHRKO rats after BNF exposure, while it was evident in 
littermate WT rats. However, two AHR antagonists tested, CH-223191 and GNF351, 
were unable to alleviate FICZ- and C2-induced avoidance behaviour, but this was 
probably due to insufficient doses and/or pharmacokinetic reasons, as they appeared 
to be generally unable to antagonise AHR function in this experiment, revealed by the 
clear induction of hepatic Cyp1a1. Moreover, in contrast to the outcome with the AHR 
agonists, strong phenobarbital-like induction of xenobiotic metabolising enzyme 
activity following exposure to a CAR agonist, TPD, did not elicit the avoidance 
behaviour, as shown in I. Therefore, novel food avoidance behaviour appears to be 
specifically and exclusively dependent on AHR activation and induced by both 
exogenous and endogenous AHR agonists. 
Interestingly, there were differences in the duration of the avoidance behaviour 
induced by the different AHR activators tested (Figure 9). Earlier, TCDD induced 
avoidance that persisted much longer than with the other compounds, lasting 14 days 
with constant ad libitum access to the novel food. The shortest effect in this study was 
seen with FICZ (~1 day), while the effects of BNF, BaP and C2 lasted for 2–3 days. 
These differences are probably due to at least three reasons. Firstly, the doses of 
the test compounds were not comparable in potency, as they were selected based on 
previous literature data to provide a reliable induction of drug-metabolizing enzymes 
in the liver. In particular, the 150 mg/kg dose used for BaP was quite high, and at 100 
mg/kg ig BaP has been reported to cause adverse effects in rats, including a transient 
reduction in motor activity (Knuckles et al. 2001, Saunders et al. 2002). Secondly, the 
test compound mixtures differed due to technical reasons, and BNF and BaP were 
administered as suspensions, while FICZ and C2 were solutions. This could have 
slightly affected the durations of the effects induced by BNF and BaP, as absorption 
from suspensions may be prolonged compared with solutions. However, the effect of 
100 mg/kg C2, dosed as a solution, also persisted for ~3 days. Thirdly, and 
conceivably most importantly, it appears likely that the durations reflect differing 
elimination half-lives of the compounds tested, even though neither this study nor 
available literature data allow its precise verification. However, TCDD has a biological 
half-life of approximately 3 weeks in rats (H. J. Geyer et al. 2002, Piper et al. 1973, 
Pohjanvirta et al. 1990), while FICZ is known to be metabolized very rapidly in 
mammals (Wincent et al. 2012). Kinetic data are lacking for C2 and BNF, but BaP or 
its metabolites may persist for several days in certain tissues (Ramesh et al. 2001). 
For C2, based on the results in I–III, metabolism also appears to be clearly more rapid 
than that of TCDD. 
Further characterisation of the novel food avoidance behaviour in I revealed that 
when rats initially had merely 6 h of access to chocolate upon exposure to the AHR 
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activators FICZ or BNF, the avoidance response was still clearly present two weeks 
later when chocolate was offered again. This could suggest that AHR activation is 
essential in triggering the avoidance, but might no longer be required during its 
maintenance. On the other hand, in the second encounter, chocolate avoidance did 
subside at a faster rate than in the first one. Thus, at this point, the results concerning 
the role of the AHR in maintaining the avoidance of novel foods are inconclusive. 
Furthermore, although both nausea and gastrointestinal malaise are subjective 
experiences and thus poorly amenable to studying in laboratory animals, earlier 
results with TCDD as well as the results in I suggest that malaise is not a critical 
prerequisite for AHR-mediated novel food avoidance behaviour in rats. For both BaP 
(Saunders et al. 2002) and TCDD (Pohjanvirta et al. 1994), doses higher than those 
employed in these and previous novel food avoidance studies have been reported not 
to cause malaise in rats. Additionally, all the three C2 doses (single 4, 20 and 
100 mg/kg) eliciting a comparable, reliable and substantial novel food avoidance 
response were far below those causing overt toxicity. 
6.2.2 The AHR and novel food avoidance: a connection to CTA? 
The results of this study were not conclusive as to the primary behavioural 
phenomenon underlying the AHR-agonist-induced avoidance of novel foods and its 
possible connection to CTA. This was mainly due to technical reasons limiting the 
experimental design. However, the design used in the second, currently unpublished 
experiment with the AHRKO rat line did allow exploring this question, as for CTA to 
develop, the association of the taste (or odour) of the CS with the avoidance stimulus 
(US) is essential. Furthermore, in classical CTA designs the CS is typically presented 
prior to the US. Here, even when chocolate (CS) was first offered for ~24 h prior to 
exposure (US), and both WT and KO rats readily consumed it then, avoidance 
behaviour was evident after exposure in the WT BNF group, but non-existent in the 
KO BNF group (Figure 10). This indicates that CTA may well be involved. There are 
also several previous results, reviewed in chapter 2.4, pointing towards CTA, although 
other prior results suggest the involvement of neophobia. 
The acquisition of CTA is due to neural processing by the brain, which integrates 
the CS with the consequences of the US (Bermudez-Rattoni 2014). The signal may be 
transmitted to the brain by neural afferents or humorally, but the physiological site 
where it originates can be difficult to identify, especially in the absence of an obvious 
symptom, such as malaise. In I, the results from one outlier rat had suggested that 
AHR activation in the stomach or upper gastrointestinal tract might be a possible 
initial key target for the avoidance behaviour. However, based on a third, currently 
unpublished experiment, the vagus nerve, which transmits sensory input from the 
digestive tract to the brain, does not seem to be involved in conveying this behavioural 
effect to the nervous system. Nevertheless, the digestive tract remains a credible 
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peripheral site for the novel food avoidance effect, and signals from there could be 
transmitted via other routes. 
Astrocytes, an abundant cell type of the central nervous system (CNS), are 
interesting regarding this matter. They are specialised glial cells that have important 
and diverse roles in health and disease, and have been shown to regulate metabolism, 
modulate neuronal transmission and be involved in CNS development and repair 
(Rothhammer et al. 2016, Sofroniew and Vinters 2010). In addition, astrocytes 
appear to be involved in CNS autoimmunity, for instance in the pathogenesis of MS 
and EAE. Furthermore, they have been shown to limit CNS inflammation following 
exposure to AHR agonists originating from dietary tryptophan and metabolised by 
the gut microbiota (Rothhammer et al. 2016). Therefore, it is conceivable that 
astrocytes could be involved in conveying also other effects induced by AHR agonists 
in the gastrointestinal tract, including the signals resulting in novel food avoidance. 
 
As discussed earlier, in addition to its several physiological functions, AHR signalling 
mediates toxic effects resulting from exposure to xenobiotics. Therefore, it is 
conceivable that it has been an evolutionary advantage to develop a system that 
detects and appropriately responds to even small changes in its activity. Furthermore, 
considering that many bHLH-PAS proteins are sensors responding to environmental 
and cellular signals (Furness et al. 2007, Gasiewicz and Henry 2011, Gu et al. 2000), 
it would not be surprising if one important physiological function of the AHR were to 
act as a sensitive sensor producing an early protective response to potentially harmful 
ingested foods. The ability of the AHR to bind compounds with various structures 
would be highly beneficial in this task, as it is valuable for the survival of organisms 
to consume any nutrition available. Moreover, as briefly discussed under Dietary 
AHR modulators in chapter 2.2.1, many dietary AHR modulators are frequently 
present in the GI tract, and it is plausible that they could have additive, potent local 
effects. Finally, it is highly interesting that in previous studies with TCDD, a 
particularly strong and persistent avoidance response developed towards chocolate 
over cheese, sucrose and saccharin solutions (Lensu et al. 2011a, J. T. Tuomisto et al. 
2000). There may be several explanations for this, but an intriguing possibility are 
flavonoids and other polyphenols, which are present in cocoa and chocolate in high 
quantities (Katz et al. 2011, Lamuela-Raventós et al. 2005, Vinson et al. 1999), and 
might be able to potentiate the effect of the administered AHR agonist. 
In addition to providing formal confirmation that AHR signalling is a necessary 
and sufficient mediator of AHR-agonist-induced novel food avoidance behaviour in 
rats, this study raises several questions concerning the novel food avoidance 
behaviour triggered by AHR activation for future research. First, it would be 
intriguing to confirm whether there is a relationship between it and CTA. Most of the 
known inducers of CTA, including the “gold standard” lithium chloride (LiCl), have 
not been reported to exhibit AHR activation. However, very few of them have been 
examined for this property, and it is also possible that they could affect the AHR 
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through non-canonical signalling. For example, LiCl is a known GSK3b-inhibitor and 
thus a Wnt signalling activator, and Wnt signalling in turn can modify AHR activity 
(Grimes and Jope 2001, Klein and Melton 1996, Schneider et al. 2014). Examining 
the effect of LiCl in the AHRKO rat model would thus be of great interest. Second, the 
critical site(s) of AHR activity for the avoidance response and the mechanism by 
which the signal is then delivered to the CNS call for further scrutiny. 
Finally, the possible repercussions of these findings for humans remain to be 
established. CTA is a common clinical problem in human medicine with chemo- and 
radiotherapy, and may also emerge in other nausea-inducing conditions, such as food 
poisoning and motion sickness (Arwas et al. 1989, Bernstein 1985, Scalera 2002). It 
has even been utilized in alcoholism treatment as “emetic therapy” (Elkins 1991). In 
theory, it could be possible to target the AHR in treatment of these conditions or, for 
instance, obesity. However, it is perhaps more likely that the relevance for humans 
related to this intriguing effect would come through increased understanding of the 
physiological functions of the AHR in the gastrointestinal tract. Indeed, information 
on other such functions are already emerging. Those encompass particularly impacts 
on intestinal inflammation, microbiota, energy balance, obesity and related steatosis 
(Hubbard et al. 2017, Moyer et al. 2016, Moyer et al. 2017, Pohjanvirta 2017, L. Zhang 
et al. 2015). Therefore, the role of the AHR in feeding behaviour might also have 
broader implications in the future. 
Particularly, the microbiota of the gastrointestinal tract may prove to be important 
in relation to the novel food avoidance behaviour. The gut microbiota and host 
immune system are known to interact and to regulate each other (C. H. Kim 2018). 
For instance, host genes have been shown to have an impact on the composition and 
function of the microbiota of the gastrointestinal tract, resulting in alterations in the 
production of microbial metabolites and intestinal inflammation (Lamas et al. 2016). 
Furthermore, one of the mechanisms by which the microbiota regulate the host 
metabolism and immune system is by production of metabolites (C. H. Kim 2018). As 
briefly discussed in chapter 2.2.2, several endogenous tryptophan metabolites are 
AHR agonists and appear to have important roles in the mammalian gut immune 
homeostasis. Interestingly, also different types of microorganisms in the gut have 
been shown to metabolise tryptophan into AHR-active compounds, and immune cells 
are known to express the AHR (Jin, Lee, Sridharan et al. 2014, C. H. Kim 2018, Wille 
et al. 2001, Zelante et al. 2013). Such metabolites have, for instance, been shown to 
balance mucosal reactivity in mice (Zelante et al. 2013). Therefore, a microbiota-AHR 
axis in the gut may prove to be important in the immunity of vertebrates 
(Rothhammer et al. 2016, Zelante et al. 2013). Concerning novel food avoidance, this 
could also be of significance regarding microbial contamination of food and formation 
of toxic or infectious material. The possibly resulting food avoidance behaviour would 
protect organisms from further adverse effects, offering them an evolutionary 
advantage. 
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7 CONCLUSIONS 
1) The active SAHRMs C1 and C3 are not cytotoxic or mutagenic in vitro, but 
they are very potent and effective activators of the AHR, in fact comparable to 
TCDD. Based on in silico modelling and validation of the analysis by in vitro 
experimentation, both C1 and C3 bind to the LBD in the rat AHR in a manner 
very similar to that of TCDD, occupying the central region of the ligand-
binding cavity. 
2) The prodrug SAHRMs C2 and C4 are also potent in vivo activators of the AHR 
in rats. However, they lack some major characteristic toxic effects of TCDD. 
In addition, overall, their observed effect profiles appear distinct from that of 
TCDD, and pharmacokinetics is likely to play a role in this. 
3) Both novel SAHRMs are promising compounds that may have potential as 
pharmaceutical molecules, and as valuable tools in further elucidating the 
multifaceted physiological roles of the AHR and the underlying molecular 
mechanisms. 
4) Induction of novel food avoidance in rats is not limited to TCDD, but other 
AHR agonists also induce it, including endogenous and exogenous 
compounds and the SAHRM C2. The effect appears to be specifically and 
exclusively dependent on AHR activation. CTA may be involved, although 
further studies are warranted to investigate its involvement. 
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